University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2019

Insight Into Acetyl-Coenzyme A Regulation Through The
Molecular Mechanism Of Atp-Citrate Lyase
Gleb Bazilevsky
University of Pennsylvania, gbazilev@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biochemistry Commons, and the Biophysics Commons

Recommended Citation
Bazilevsky, Gleb, "Insight Into Acetyl-Coenzyme A Regulation Through The Molecular Mechanism Of AtpCitrate Lyase" (2019). Publicly Accessible Penn Dissertations. 3492.
https://repository.upenn.edu/edissertations/3492

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3492
For more information, please contact repository@pobox.upenn.edu.

Insight Into Acetyl-Coenzyme A Regulation Through The Molecular Mechanism
Of Atp-Citrate Lyase
Abstract
The metabolite acetyl-CoA is necessary in almost all organic life. Cytosolic acetyl-CoA is crucial for lipid
synthesis, cholesterol synthesis, and gene regulation. It is also a major factor in metabolic disorders,
including diabetes, heart disease, and cancer. In metazoans, the predominant source of cytosolic acetylCoA is the essential enzyme ATP-citrate lyase (ACLY). This enzyme is a prime pharmacological target.
However, the molecular mechanisms of ACLY activity and regulation are unclear. This work uses a suite of
biochemical and biophysical approaches to elucidate ACLY quaternary structure and the mechanisms of
acetyl-CoA synthesis. We demonstrate that ACLY forms a tetramer through the previouslyuncharacterized ACLY C-terminus. The C-terminus, in the context of the tetramer, interacts with the rest of
the protein to bind the reaction substrates. This is a new model for ACLY substrate binding and enzyme
activity. We also explore the direct interaction of ACLY with protein acetyltransferases as a means of gene
regulation. These findings have implications for our basic understanding of protein biology, evolution, and
the rational design of life-saving ACLY therapies.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Ronen Marmorstein

Keywords
acetyl-CoA, enzymology, metabolism, protein biophysics, protein structure

Subject Categories
Biochemistry | Biophysics

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3492

INSIGHT INTO ACETYL-COENZYME A REGULATION THROUGH THE MOLECULAR
MECHANISM OF ATP-CITRATE LYASE
Gleb Bazilevsky
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2019
Supervisor of Dissertation
_________________________
Ronen Marmorstein
George W. Raiziss Professor

Graduate Group Chairperson
_________________________
Daniel S. Kessler, Associate Professor of Cell and Developmental Biology
Dissertation Committee
Roger A. Greenberg, J. Samuel Staub, M.D. Professor
Joseph A. Baur, Associate Professor of Physiology
Ben E. Black, Professor of Biochemistry and Biophysics
Shelley L. Berger, Daniel S. Och University Professor

Dedication page

I dedicate this work to my parents: Anatoly and Natalya Bazilevsky, с увожением.
I dedicate this work to the root of our craft: “ο δ ανεζεταστος βιος ου βιωτος ανθρωποι.” 1

1

“THE UNEXAMINED LIFE IS NOT WORTH LIVING.” PLATO'S APOLOGY (38A5–6)

ii

ACKNOWLEDGMENT
First kudos must go to the laboratory. A laboratory is a living entity, quickened to life by the
Principal Investigator and embodied by its members. This work is due entirely to Ronen
Marmorstein’s guidance, mentorship, and support. I am grateful to lab members past and
present for the exchange of material and ideas, shared freely and made greater in the sharing.
They are inspirations, one and all. Particularly, I thank Xuepeng Wei for his insights into the ACLY
molecular mechanism. I thank Elliot Dean and David L. Schultz for assisting with protein
production in Sf9 cells for this study. Lastly, I thank Dr. Adam Olia for being a dutiful mentor,
eternal advisor, and occasional gadfly.
I also owe much to Dr. Kathryn E. Wellen, for half a decade of collaboration. There would be no
story here without her knowledge and understanding of ACLY, let alone her data. Special
mention is reserved for Dr. Kushol Gupta for helpful discussions about analytical
ultracentrifugation and protein biophysics.
Mention is also necessary for the Proteomics Core Facility at the Wistar Institute, the DNA
Sequencing Facility, and the Perelman School of Medicine, University of Pennsylvania. This work
was supported by National Institutes of Health Grants R35 GM118090 and P01 AG 031862 (to
R.M.), and F31CA189559-01 (to G.A.B.). It would not do to omit that this content is solely the
responsibility of the author and does not necessarily represent the official views of the National
Institutes of Health.
I also wish to acknowledge one point two billion years of evolution, without which none of this
work could have been possible.
iii

ABSTRACT
INSIGHT INTO ACETYL-COENZYME A REGULATION THROUGH THE MOLECULAR
MECHANISM OF ATP-CITRATE LYASE
Gleb Bazilevsky
Ronen Marmorstein

The metabolite acetyl-CoA is necessary in almost all organic life. Cytosolic acetyl-CoA is crucial
for lipid synthesis, cholesterol synthesis, and gene regulation. It is also a major factor in metabolic
disorders, including diabetes, heart disease, and cancer. In metazoans, the predominant source
of cytosolic acetyl-CoA is the essential enzyme ATP-citrate lyase (ACLY). This enzyme is a prime
pharmacological target. However, the molecular mechanisms of ACLY activity and regulation are
unclear. This work uses a suite of biochemical and biophysical approaches to elucidate ACLY
quaternary structure and the mechanisms of acetyl-CoA synthesis. We demonstrate that ACLY
forms a tetramer through the previously-uncharacterized ACLY C-terminus. The C-terminus, in
the context of the tetramer, interacts with the rest of the protein to bind the reaction substrates.
This is a new model for ACLY substrate binding and enzyme activity. We also explore the direct
interaction of ACLY with protein acetyltransferases as a means of gene regulation. These findings
have implications for our basic understanding of protein biology, evolution, and the rational design
of life-saving ACLY therapies.
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PREFACE
Food is life. Our imperative therefore is to understand the consequences of food on life. This
work aspires to be a small piece in a large machine, working to understand the effect of the
foods we eat on the way we live.

x

CHAPTER 1: INTRODUCTION
The Centrality of Carbohydrates
Life is made possible by the coordinated deployment of chemical processes to reverse the local
entropy within our semi-permeable systems. Our broader environment does not take our
efforts lightly. The effort of life requires energy1. For some organisms, energy comes from light.
For some, it comes from heat. For us, it comes from lunch. Regardless of what we consume,
some proportion of our intake is processed into glucose, the cellular carbon source of choice.

Glucose Metabolism on the Organismal Level
We are resourceful omnivores. Glucose is one of many exogenous organic molecules that we
consume for energy and biological building material. Fats, glutamine, and other amino acids
contribute to total cell mass at least as much as glucose2. Yet, several cell types are obligate
glucose consumers, such as renal medullary cells, red blood cells, and neurons3. Actively
proliferating cells in particular rely on glucose4–6.
Humans have evolved elaborate systems of regulating glucose in the liver and across the entire
organ network7. The liver expends significant energy to maintain blood glucose levels.
Competing insulin and glucagon hormones signal hepatic cells to decrease or increase blood
glucose through the careful balance of glycogenesis (glucose uptake) against gluconeogenesis
and glycogenolysis (glucose release)3. The liver must be dynamic and resilient to adequately but
not excessively supply glucose to the rest of the body. Yet, we know that too much glucose can
stress this system to the point of serious negative health outcomes.
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Metabolic Dysfunction
As the global human population has evolved and spread, so too has agriculture, food
production, and average caloric intake. This expansion of food availability has driven human
proliferation and the development of complex societies8. Social, political, and technological
development have created a positive feedback loop of agricultural efficiency and overall per
capita food yield.
The arc of human technological progress, particularly since the Industrial Revolution, has
produced the twin phenomena of abundant food availability and reduced physical activity9. Now
more than ever, more calories are taken in and fewer calories are expended. The result is a net
excess of consumption, especially of the high-calorie, carbohydrate-rich foodstuffs universally
found delicious. Excess consumption has brought with it an increase in the incidence of dietrelated health problems. There is a causal link between carbohydrate consumption and the
onset and severity of obesity, diabetes, and cardiovascular disease10,11.

Obesity
Obesity is defined ad hoc as the excessive energy intake and body mass accumulation sufficient
to damage health12. It is the direct result of the strain placed on the body by superfluous
calories. With the increase in global caloric intake there has been a commensurate spread of
global obesity. To be fair, every individual has a different likelihood of becoming obese. The
response to caloric excess can be influenced by genetic factors, such as variations in cold
tolerance genes13, and by environmental factors, such as a diet significantly made up of simple
sugars14. Although individuals have unique predispositions for or against body mass
accumulation, excessive caloric intake will inevitably bring the body to crisis. Once a person has
2

crossed over their innate body mass threshold, there is a cascade of severe health
consequences15.

Cardiovascular disease
Excess consumed glucose is converted to triglycerides and cholesterol. These lipids are turned
into white fat and to low-density lipoprotein (LDL). The hepatic production of triglycerides and
cholesterol directly contributes to the risk for developing major cardiovascular disease, while
the accumulation of LDL causes coronary atherosclerosis. Coronary atherosclerosis is the leading
cause of coronary artery disease and ischemic heart disease, the most fatal disease in the United
States16.

Diabetes
Diabetes is one of the consequences of our evolutionarily-perverse predicament. Adult-onset
diabetes is a broad collection of symptoms related to the loss of insulin production or sensitivity.
The end result is the dysregulation of circulating glucose. Globally, one in eleven people have
diabetic symptoms, 90% of which are adult-onset (type II) diabetes, diabetes mellitus. In a single
year, it is expected to account for almost 1 trillion dollars in health spending. Worse still, it at
least doubles the risk of death. This year, it will directly or indirectly contribute to the death of
approximately 5 million people worldwide17,18.

Cancer
Furthermore, metabolic dysfunction can create opportunities for other disorders that thrive
under chaos, such as cancer. Cancer is the product of environmental opportunity and genetic
instability. It can result from numerous systemic disorders including disequilibrium in cell
3

metabolism19. The result is the unchecked proliferation of cells that can interfere with the
function of physiological systems. These unproductive, hyper-proliferative cells are insatiable for
the fundamental resources that allow continued proliferation, especially glucose20. The visible
and visceral pathology of this disease have engendered feverish efforts to understand cancer
development.
The treatment of metabolic dysfunction requires multi-pronged approaches for therapy
development. Therapeutics that decrease circulating glucose and LDL levels, such as metformin
and statins, respectively, have been revolutionary advances in mitigating lethality. However,
these drugs were serendipitous discoveries in natural sources. As powerful as the combined
force of luck, observation, and ingenuity have been to find and adapt these natural products,
most were not evolved by their native organisms to affect human metabolic pathways. Thus,
there is more risk of unintended consequences and off-target effects. We must become more
systematic and rational in therapeutic development, in order to avoid unintended harm as
health risks propagate and require more complex, combinatorial treatments. To do so we must
understand metabolic disorders at their macro and micro levels.

Glucose Metabolism on the Cellular Level
Our knowledge of glucose metabolism began with the observations of Louis Pasteur in the
1850s that yeast grew differently with and without air. A hundred years later, Embden,
Meyerhof and Parnas developed the full outline of the molecules and enzymes involved21. The
elucidation of the aerobic glycolysis pathway eventually tied into the contemporaneous
elucidation of the tricarboxylic acid (citric acid or TCA) cycle, and the citrate molecule.
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Glucose
Glucose is actively transported into cells and then broken down in the cytosol through glycolysis.
The final product of the glycolytic pathway is pyruvate. Once produced, pyruvate translocase
imports the molecule into the mitochondrion, where the pyruvate dehydrogenase complex
cleaves pyruvate through oxidative decarboxylation and then condenses the intermediate with
coenzyme A (CoA; discussed below) to produce acetylated coenzyme A (acetyl-CoA or Ac-CoA).
This product is then condensed by mitochondrial citrate synthase with oxaloacetate to release
the eponymous molecule of the cycle, citrate22.

Citrate
Citrate is the salt form of citric acid, which occurs naturally in citrus fruits, some vegetables, and
the products of fermentation23. It is a small, polar, achiral electrophile. It is tribasic, with pKa
values of 2.92, 4.28, and 5.21 at 25°C24. It is a weak acid, a decent buffer, and a strong metal
chelator25,26. Citric acid was first isolated by Carl Wilhelm Scheele in 1784, who was principally
interested in controlling the acidity of wine. For centuries afterwards, citrate was used in food
and industrial chemistry as an acidifier, flavoring agent, chelator, and a base component for
pharmaceutical synthesis27.

Citrate in Metabolic Pathways
In the mid-century, Albert Szent-Györgyi von Nagyrápolt and Hans Adolf Krebs recognized that
citrate was the primary reactant in the citric acid cycle and that citrate participated in animal
metabolism28. For these insights, Szent-Györgyi won a Nobel Prize in 1937 and Krebs in 195329.
Although the details of their insights and the component reactions of citric acid cycle are beyond
the scope of this discussion, it is important to note that this process nimbly cycles Ac-CoA to
5

oxidize the glucose-derived acetyl group to carbon dioxide, transferring the chemical energy to
NADH, FADH2, and GTP. These molecules provide energy for downstream mitochondrial
processes such as oxidative phosphorylation, which couples the reduction of oxygen to the
production of huge amounts of ATP. ATP is ultimately the energy donor for the majority of
cellular activities. Along the way, as citrate is produced in the citric acid cycle, it is free to diffuse
across the mitochondrial membrane into the cytosol22.
Depending on the cellular compartment, citrate is cleaved by different enzymes to provide a
two-carbon acetyl building block for larger organic molecules. This acetyl elementary unit is
needed for every anabolic process in the cell, from amino acid synthesis to terpenoid synthesis
to cholesterol synthesis. It is also part of the control of gene transcription and protein function.
Thus, glucose levels can influence cell behavior. However, citrate-derived carbon must be
carried to the enzymes that use it for anabolism. It is carried by the omnipresent metabolite,
CoA.

Acetylated Coenzyme A is at the Nexus of Metabolic Pathways
CoA is a workhorse of carbon transport among all three domains of life30. Studies of prebiotic
pantothenate stability and reactivity suggest that the pantothenate pathway, including CoA
synthesis, was present at the dawning of Life on Earth31,32.
Pioneering biochemist Fritz Lipmann first extracted CoA in 194633. He demonstrated that CoA
and acetylated CoA were prolific participants in cellular respiration and neuronal acetylcholine
signaling34,35. This work eventually earned Lipmann the 1953 Nobel Prize in Physiology, shared
with Krebs for his work on the citric acid cycle.
6

CoA Structure and Chemistry
Lipmann eventually found that CoA is derived from the condensation of the amino acid cysteine,
ATP, and pantothenate (vitamin B5)30,36,37. The reduced thiol moiety of the cysteine group
provides a chemical handle for acylation; it is a nucleophilic warhead for carbonyl activation.
This functionality makes CoA indispensable for metabolic biochemistry. The thiol has a low
activation energy; it is easily acylated and deacylated, and so is a versatile single carrier for
different carbon chains that is able to rapidly accept and deliver its cargo. Of these acylations,
the most ubiquitous and flexible is acylation to acetyl-CoA (Ac-CoA).

Sources
CoA and Ac-CoA are membrane-impermeable, and so different cellular compartments must
actively transport the molecules or produce their own pools for carbon shuttling38–40. CoA is
acetylated by different pathways depending on the nutritional environment, cell type, and
cellular compartment. For example, the mitochondrion produces Ac-CoA from pyruvate through
the pyruvate dehydrogenase complex, while the peroxisome produces Ac-CoA from fatty acid βoxidation. In hippocampal neurons41 or more broadly during low oxygen availability42, cells
prefer to directly condense CoA with acetate. In the cytosol, this proceeds through the activity
of acetyl-CoA synthetase 2 (ACSS2). ACSS2 may also compensate during glucose starvation43–45.
Yet, in a glucose-rich environment where aerobic glycolysis is possible, citrate cleavage becomes
major source of cytosolic Ac-CoA46.

Role in the Cell
Regardless of the source, Ac-CoA is the cellular carrier du jour for the acetyl functional group.
Because of its very simplicity, the acetyl group is the basis for the synthesis of larger carbon
7

chains. Ac-CoA becomes the first reactant in several major anabolic pathways, including lipid
synthesis and cholesterol synthesis. The former pathway begins with malonyl-CoA formation,
followed by additional esterification reactions to produce free fatty acids and triacylglycerides.
The latter pathway converts acetyl-CoA to mevalonate and then to squalene, which is cyclized
and modified into cholesterol39.
Ac-CoA is the sole acetyl donor for protein acetylation47. Protein acetylation is a conserved facet
of the epigenetic control of cell fate48. The field of Epigenetics was born from Conrad
Waddington’s idea that there existed a communication between genes and phenotypes that
could not be explained by genetic principles49. Today we know that this communication includes
covalent modifications like protein acetylation, which is carried out by protein
acetyltransferases50. Protein acetylation is a flexible means of regulating activity by changing
biochemistry, affecting protein-substrate or protein-protein interactions that in part define the
protein’s overall behavior and destiny51. One of the most studied protein acetylation
phenomena is the acetylation of histone proteins, which are responsible for the compaction and
organization of deoxyribonucleic acid (DNA). When acetylated, histones lose some of their basic
character, i.e. positive charge, allowing the negatively charged DNA backbone to repel itself,
thus relaxing the local genetic architecture52,53. The underlying genes then become more
accessible to transcription factors and the transcription machinery. In this way, protein
acetylation is a major mechanism of altering gene expression levels54,55. Histone acetylation is
ubiquitous across the entire genome; it might be activating or inhibitory depending on its
location and combination with other histone modifications56. Precise control of gene expression
through the use of Ac-CoA is necessary for healthy cell function.
8

Dysfunction in Metabolic Disorders
The effects of glucose on human health and disease have their molecular basis in the intricate
cycling of the metabolites that maintain energetic equilibrium. These intricate cycles guarantee
an adaptability that keeps our complex cellular and organismal systems ready to respond to all
manner of environmental changes. However, this intricacy creates many opportunities for
things to go awry. Ac-CoA is an inextricable component of glucose metabolism, and the
dysregulation of Ac-CoA is an inextricable part of metabolic disease.

Acetyl-CoA in the study of cardiovascular disease
The link between glucose metabolism and cardiovascular disease is well defined. As glucose is
consumed, more mitochondrial and cytosolic Ac-CoA is produced. In the cytosol, Ac-CoA is the
starting point of cholesterol synthesis as part of the mevalonate pathway57,58. All endogenous
cholesterol synthesis depends on Ac-CoA. With the production of more Ac-CoA comes more
cholesterol, circulating LDL, and a commensurate increase in arterial lipid deposition. This
relationship works in the reverse as well. Pre-symptomatic targeting of circulating LDL can
dramatically reduce atherosclerotic heart disease59. Reducing LDL has significant health benefits
for both genders, across a wide age spectrum59–61. On the molecular level, it is apparent that the
inhibition of cytosolic Ac-CoA utilization pathways decreases cellular lipid levels and the overall
incidence of atherosclerosis62.

Acetyl-CoA in the study of cancer
Many types of cancers shift from oxidative respiration to glycolysis as their major energy
source20,63. This phenomenon was first commented on by Otto von Warburg, and so bears his
name64. During carcinogenesis, an increase in glycolysis is used to fuel the de novo synthesis of
9

fatty acids and cholesterol for lipid membranes. Inhibition of cytosolic Ac-CoA production can
arrest cancer cell growth, with minimal effect on the health of nonproliferating (quiescent)
cells42,65,66. Yet, this is not sufficient explanation of the link between increased Ac-CoA levels and
the actual onset of cancer. We know cells use Ac-CoA levels to gauge the nutritional
environment67–69. The cell treats high Ac-CoA availability as a proxy for a nutrient-rich milieu. AcCoA can stimulate cells to divide, activating the same genes and pathways that become
dysregulated in cancers70–72. However, we do not yet understand the process of causation. Does
the increased availability of Ac-CoA trigger more protein acetylation? Is this effect global,
causing more flux in gene expression across the entire genome? Is the effect local, somehow
targeting specific growth-promoting genes? The transition from a healthy quiescent cell or a
healthy replicating cell to an unhealthy replicating cell remains unclear. Still, Ac-CoA must play
some part in this disease.

Acetyl-CoA in the study of ageing
The notion of health too is unclear. Every corner of the living world lives in the knowledge that it
must eventually die. Ageing is an inevitability. Yet, ageing is a variable process, with many
determinants of the arc between life and death. Acetyl-CoA, as a multifaceted participant, is one
of these determinants. Multiple groups have observed that the limited inhibition of Ac-CoA
availability has real, beneficial effects on age progression and organismal lifespan73,74. This effect
might operate in the same realm as the efforts that target histone acetyltransferases and
deacetylases75,76.
In summary, there are many tangible and intangible benefits to human health and wellness that
will come with the further study of the mechanisms of Ac-CoA regulation.
10

Thesis Aims
The regulation of acetyl-CoA levels in the cell is a potent means of controlling gene expression
and cellular behavior, with profound consequences for health and longevity. However, we do
not yet understand how the levels of acetyl-CoA are modulated. It is also unclear how acetylCoA levels influence gene expression. Here we used biochemical and biophysical tools to
investigate one of the major avenues of acetyl-CoA production: synthesis through the essential
enzyme ATP-citrate lyase. We explore the molecular configuration that is necessary for optimal
ATP-citrate lyase activity. We hypothesize that the multimerization of this enzyme is an essential
characteristic necessary structural stability and substrate binding.
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CHAPTER 2: ATP-CITRATE LYASE MULTIMERIZATION IS REQUIRED FOR
SUBSTRATE BINDING AND CATALYSIS

Background
ATP-Citrate Lyase
Among the majority of eukaryotes, nuclear and cytosolic acetyl-CoA is derived from glucose by
the TCA cycle through the enzyme ATP-citrate lyase (ACLY; E.C. 2.3.3.8)67. This enzyme is
essential to mammalian survival77. The pathways that control lipid production39 and protein
acetylation42,47,78 often target ACLY to affect Ac-CoA levels.
The importance of ACLY is evident in the effects of ACLY inhibitory therapeutics. The knockdown
of ACLY hits hard at cells; knockdown results in a profound decrease in protein acetylation, fatty
acid synthesis, and cell proliferation79. ACLY inhibition has been one of the most promising
avenues for treating dyslipidemia79,80 and cardiovascular disease62,81,82. Moreover, the inhibition
of ACLY arrests fast-growing, malignant cells without harming slow-growing, healthy ones65,83.
During carcinogenesis, ACLY activity is stimulated through the growth-promoting PI3K/Akt
signaling pathways84. This increase in ACLY promotes cancer cell growth, while inhibition of ACLY
impairs cytokine-stimulated cell proliferation, and Akt-mediated tumorigenesis85. Despite a
number of inhibitors that have been developed and tested, there is still much progress to be
made in their potency and selectivity80,86–88. To this end, we committed significant effort to the
mechanistic study of ACLY as an opportunity for the development of new and better treatments.
12

The Enzymatic Reaction
In order to understand the molecular basis for ACLY function, we must first elaborate on knowns
and unknowns of the enzyme’s catalytic mechanism. ACLY acts through an elaborate series of
events that convert MgATP, citrate, and CoA into ADP, acetyl-CoA, and oxaloacetate (Eq. 1-5)89–
93

. The enzyme transfers the terminal phosphate of ATP to a histidine to form a phospho-

histidine intermediate (Eq. 1)94–97. The phosphohistidine intermediate then becomes more
attractive to citrate (Eq. 2). Upon citrate binding, there is an electronic rearrangement of the
phosphate to the citrate, forming citryl-phosphate (Eq. 3)98. CoA enters into the active site and
carries out a nucleophilic attack to liberate the phosphate and form a citryl-CoA intermediate
(Eq. 4). Finally, a general base within the enzyme likely cleaves the citryl-CoA through a retroClaisen reaction to produce acetyl-CoA and oxaloacetate (Eq. 5)93,99–101. Here are the proposed
reaction schema:
E + MgADP~P ⇀ E~phosphate · Mg2+ + ADP

(Eq. 1)

E~phosphate · Mg2+ + citrate ⇌ E~phosphate · Mg2+ · citrate

(Eq. 2)

E~phosphate · Mg2+ · citrate ⇌ E · citryl~phosphate · Mg2+

(Eq. 3)

E · citryl~phosphate · Mg2+ + CoASH ⇀ E · citryl-CoA + Pi

(Eq. 4)

E · citryl-CoA ⇌ E + acetyl-CoA + oxaloacetate · Mg2+

(Eq. 5)

E = enzyme; “-“ covalent bond; “~” labile covalent bond; “·” noncovalent interaction
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These reactions proceed as shown in Fig. M1, and the full reaction mechanism is shown in Fig.
A1.

Figure M1. Catalysis involves a multi-step reaction mechanism. Reaction rate constants and KM values are from
the experimental data in Table M1 and from Fan et al.89

The work of Fan et al. provides some understanding of the pre-steady-state and steady-state
parameters of these reactions93. First, ATP hydrolysis quickly produces a large proportion of
stable enzyme-phosphate intermediate before any other reaction occurs. The phosphatebearing histidine is likely a deprotonated histidine 760 (H760), with a pKa of 7.5. This histidine is
conserved in all known ACLY sequences (Fig. A2), and has been validated in bacterial ACLY102.
Next, the binding of citrate occurs (Eq. 2). Although citrate can bind ACLY without ATP, the
reaction becomes more favorable after autophosphorylation, as does the binding of CoA after
the formation of the citryl-phosphate intermediate (Eq. 4). These rearrangements (Eq. 2-4) are
fast and have near-equal kforward/kreverse ratios, suggesting significant reversibility. Interestingly,
the citryl-CoA cleavage reaction (Eq. 5) can occur independently of the other reaction steps, as
the enzyme is fully capable of cleaving exogenous citryl-CoA to the OAA and Ac-CoA products101.
These studies also demonstrated that the enzyme must be stereoselective, phosphorylating only
one carboxylate arm of citrate, called the proto- or pro-S carboxyl, to exclusively form the 3-(S)citryl-CoA enantiomer. Finally, Fan and colleagues confirm that the rate-limiting step of catalysis
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is the release of MgADP. MgADP remains bound throughout the reaction, with a koff (7 s-1) that is
three times slower than all of the other measured rates. There are still many questions about
how these transition states form and which residues the enzyme uses to form them. Moreover,
it is unclear how these reactions can be regulated by other intrinsic or extrinsic factors over the
course of cellular metabolic flux.

Intramolecular Structure
The study of ACLY structure is needed to understand the ACLY molecular mechanism. The
highly-conserved enzyme sequence has two superdomains. The protein amino terminus is
strongly homologous to the NDP-forming acyl-CoA synthetase superfamily103, which we will
refer to as the acyl-synthase homology domain (ASHD; Fig. A3A-B). The protein carboxy
terminus is strongly homologous to the class I citrate synthase (E.C. 2.3.3.1) superfamily104,105,
which we will refer to as the citrate synthase homology domain (CSHD; Fig. A3C).
Catalysis in the human ACLY ortholog is thought to occur at the ASHD, spanning ACLY domains 15. These domains are structurally and functionally similar to acyl-CoA synthetases, such as
succinyl-CoA synthetase (SCS; EC 6.2.1.4)103. Like ACLY, members of this family add various acyl
moieties to CoA. Their molecular mechanisms proceed through the hydrolysis of NTPs for
histidine autophosphorylation, followed by acyl-substrate binding and condensation with CoA.
Structurally, the ACLY ASHD and SCS have homologous α/β regions, with very similar power
helices at the enzyme active site.
ACLY is also similar in sequence at the C-terminus to the citrate synthase (CS) superfamily106. CS
catalyzes the conversion of oxaloacetate and acetyl-CoA to citrate and CoA, in the reverse of the
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ACLY mechanism. The CS reaction even has the same (3S)-citryl-CoA reaction intermediate. In
silico modeling and empirical structural data propose that the CS residues H347 and D401 (in
Thermoplasma acidophilum) deprotonate Ac-CoA and stabilize the oxaloaceto-CoA enolate107.
The residues I253, G255, N310, R259, and R218 (in Thermus thermophilus) that all make contact
with Ac-CoA107,108 are also present in the C-terminus of ACLY. Therefore, it is possible that ACLY
adopts the chemistry of CS for noncanonical CoA-binding through the CSHD. This possibility is
supported by ITC evidence that ACLY cannot bind CoA without this domain109. However, this
parallel is limited by only partial conservation of the primary sequence. ACLY has only some of
the CS residues that interact with CoA and stabilize the CoA intermediates. Thus, ACLY might
have evolved to take advantage of another feature of CS, independent of substrate-binding.
CS is present across evolutionary space as a dimeric complex105. The dimerization of CS is an
essential feature, as the citrate synthase dimer interface forms the enzyme active site107,110. CS
self-association might have conferred increased structural stability as well as allowed novel
chemistry to occur at the association interface111.
ACLY is also multimeric. Size-exclusion and sedimentation studies of plant and murine homologs
suggest that ACLY forms a homotetramer112,113, although this has not been confirmed for the
human protein. The conserved multimerization of ACLY parallels the conserved multimerization
of CS.
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Outstanding Questions
The molecular mechanism of ACLY catalysis is incompletely understood. The residues that
contribute to cofactor binding and product formation remain in contention, as well as the
importance of ACLY multimerization. While previous studies have focused on the role of the
enzyme N-terminal ASHD, the C-terminal CSHD is largely uncharacterized. Further
understanding of the CSHD could present a new dimension to the study of ACLY biochemistry
and regulation.
Thus, we began our work with the idea that multimerization might play a structural and/or a
catalytic role in ACLY function. In this study we hypothesized that ACLY multimerization through
the CSHD is an essential characteristic that is necessary for the full activity and stability of the
enzyme.
We chose to study human ACLY in a cell-free system. We used recombinant protein truncations
to isolate and assess each homology domain. We studied the effect of these truncations on
enzyme activity and substrate binding.
This study confirmed that human ACLY forms a tetramer through the CSHD, which can further
interact with the ASHD to bind the CoA substrate. We propose a new paradigm for the
molecular mechanism of ACLY, in which the superdomains of ACLY cooperate through
multimerization to produce acetyl-CoA.
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The Multimerization of ACLY
Production of recombinant protein constructs
The majority of our work centered on the study of the human ACLY isoform 1 in a cell-free
system. To carry out these studies, we purified recombinant protein from both Escherichia coli
and Spodoptera frugiperda (Sf9) cells (Fig. M2).

Figure M2. Full-length and truncated recombinant ACLY can be expressed and purified. (A) Scaled
representations of ACLY constructs, with nomenclature, residue count, and monomer molar mass. Domains 1-5
are numbered according to domain arrangement in bacterial succinyl-CoA synthetase. (B) SDS-PAGE of ACLY
constructs on 12% Bis-Tris. (C) Single representative size-exclusion traces of ACLY constructs on superose 6
increase chromatography column, one experiment, n=1 for each construct. The peaks are normalized to
account for differences in loading concentrations.
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The behavior of our recombinant full length ACLY readily spoke to the evolutionary relationship
with SCS superfamily. When we expressed the full 1101-residue ACLY (ACLY-FL)114, we observed
on SDS-PAGE consistent degradation to 80 kDa and 50 kDa protein fragments that stayed
together during SEC (Fig. M2C). Protein degradation products can be predicted by analysis of the
peptide sequence using tools such as DISOPRED115. Analysis of ACLY sequence predicted
secondary structure instability at domain 5, which would generate fragments of approximately
the observed size (FIG. A4A). The DISOPRED predictions were confirmed by liquid
chromatography tandem mass spectrometry (LC-MS/MS) of the ACLY-FL and accompanying
fragments taken from the SDS-PAGE gel (FIG. A5B). This pattern appeared consistent with SCS
domain organization, and limited proteolysis experiments116. The 80 kDa fragment mapped to
human ACLY residues 477-1101. This fragment is closely homologous to the ancestral ACLY α
subunit, which in turn is homologous to the SCS α subunit. On the other hand, the 50 kDa
fragment mapped to human ACLY residues 1-452. This fragment is primarily homologous to the
ancestral ACLY β subunit, which is itself homologous to the β subunit of SCS 103,117. The α and β
homology regions are connected by a large unstructured linker, residues 426-488, in ACLY
domain 5. Breakdown to these fragments is a common problem in the purification of ACLY;
concurrent with my research others have also reported the need to delete the same
unstructured loop for stabilization and successful crystallization118,119. We compared E. coli
productions to and those in Sf9 cells, which are often used to produce protein in a eukaryotic
environment, hopefully to provide more chaperones and thus better protein folding. However,
we found the same breakdown patterns (Fig A6). There was also no significant difference in
thermal stability (Fig. A7). We combined these data to engineer stable truncations for
downstream analysis.
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We designed truncated ACLY constructs to isolate either the ASH superdomain (ACLY-Nterm 1-2)
or the CSH superdomain (ACLY-Cterm 1-4; Fig. M1). We used BLAST120, CLUSTAL121, and
ESPript122 alignment tools to compare domain boundaries by homology to bacterial SCS and CS
sequences (Fig. A3). These boundaries became the cut-off points for truncation. Expression of
the truncated sequences in E. coli displayed a wide range of overall yield and structural stability
(Fig. M2). In particular, ACLY-Nterm 1 could only be produced in Sf9 cells, while the ACLY-Cterm
1-2 constructs persistently lost additional residues in the unstructured region. Nonetheless, we
were able to attain sufficient quantities for biochemical analysis.
In addition to the production of ACLY-FL, we were able to co-express ACLY-Nterm 2 with ACLYCterm 2 in E. coli. We were able to purify them together to mimic the formation of the ancestral,
heterodimeric ACLY-α/β state123 (Fig. M2B and A6). The ACLY-α/β mimic behaved as the fulllength ACLY. The components stayed together during SEC and were identical in thermal stability
to full-length ACLY (Fig. A5 and A6). LC-MS/MS analysis did not identify any post-translational
modifications in either system (data not shown). Both our ACLY-FL and our ACLY-α/β constructs
were enzymatically active and displayed similar steady-state kinetic parameters for citrate and
CoA (Figure M3). Our bacterial ACLY-FL evidenced KMs of 18.9 ± 2.92 µM and 126 ± 19.8 µM for
CoA and citrate, respectively (Table A1). We observed slightly different values for the KM and kcat
of ACLY-α/β, with the co-expression construct more efficient at turnover (higher kcat) but less
efficient at binding cofactor (higher KM). We speculate that the co-expression is more
structurally stable, but the excised loop might participate in cofactor binding in a manner not
visible in the available structural data. After the successful purification of active ACLY, we turned
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to the first of our goals: to validate that human ACLY forms a homomultimer and biophysically
characterize the number of subunits in the ACLY homomultimeric complex.

Figure M3. ACLY-FL and ACLY-α/β have similar Michaelis-Menten-Henri steady-state enzymatic parameters. (A)
Activity series with various CoA concentrations. (B) Activity series with various citrate concentrations. Comparison of
ACLY-α/β (□) ACLY-FL protein produced in E. coli (○) or Sf9 (∆). Summary of three independent experiments, n=6 each.
The data are represented along the abscissa on the log scale for clarity.

Confirmation of Base-Mediated Citryl-CoA Cleavage
As we worked to validate the enzymology of our recombinant constructs, we also tried to add to
the understanding of the ACLY reaction mechanism. As mentioned in Chapter 1, catalysis is
thought to proceed through a base-mediated cleavage of the citryl-CoA intermediate. To date,
there is only indirect support for a general base mediating the retro-Claisen cleavage of the
citryl-CoA intermediate93,99–101. The participation of a general-base is an established idea in the
biochemistry of some acyl-synthetases124,125. However, we are the first to investigate the
biochemistry of general-base catalysis in human ACLY. To get at this question, we tested enzyme
activity across a pH range.
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Figure M4. ACLY has a
bimodal pH dependence.
MDH-coupled activity assay
across a pH gradient, with
indicated inflection points by
Boltzmann sigmoidal
analysis. One experiment,
n=5 replicates.

This profile resembled a first-order reaction. Often, the same first-order progression is related to
the equilibrium models of Irving Langmuir. First used to describe the adsorption of gas particles
onto a solid surface, this model is also frequently used to describe any rapid equilibrium with a
first-order or pseudo-first order reaction rate. This includes the movement of protons under
different bulk-solvent pH conditions, as well as amino-acyl side-chain deprotonation with
increasing pH126. The distribution of activity with increasing pH appeared bimodal, with
inflection points at pH 7.3 and pH 9.5 (Fig. M4). The first inflection is likely the catalytic histidine,
which must be deprotonated to undergo autophosphorylation. The second inflection was of
more interest to us, as it supported the idea of a second base involved in the catalysis. We
theorized that we see more activity at higher pH as LeChatlier’s Principle increases the
probability of the general base losing its proton to the bulk solvent.
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Human ACLY is predominantly a tetramer in solution
We began our study of the ACLY complex with an expansive biophysical analysis of the complex
stoichiometry. Prior to comprehensive structural information being published about the
complex119,127, we used these analyses to characterize the behavior of the ACLY multimer in
solution.
The purification of our proteins by size-exclusion chromatography (SEC) presented the first
picture of the ACLY multimerization state. Our ACLY-FL and ACLY-α/β constructs consistently
formed large multimers (Fig. M2C and A5A). The migration profile indicated that there was only
one major species (by intensity), which was surprising given the propensity of the protein to
break into pieces. However, the elution profiles were broad, spanning several milliliters instead
of a sharp, Gaussian peak in only one or two milliliters. This made it difficult to accurately
calculate the radius of gyration and apparent MW. Furthermore, we purposefully excluded
stabilizing cofactors (such as citrate) or other additives from the SEC buffer to limit potential
conformational variability. This might have led to confounding heterogeneity in the sample due
to the structural instability of these constructs already seen by SDS-PAGE.
Analytical ultracentrifugation can provide a more rigorous and quantitative determination of
subunit stoichiometry128,129. One form of analytical ultracentrifugation is sedimentation
equilibrium (SE) analysis, a shape-independent study of macromolecular molar mass130. This
approach suggested that ACLY-FL and ACLY-α/β were predominantly tetramers in solution. The
ACLY-FL data were most consistent with the formation of a single species with a global
calculated molecular weight of 452 ± 3.28 kDa, close to the expected tetramer molecular weight
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of 495 Da. When linearized, these data aligned closest to the expected distribution for a
homotetramer (Fig. M3 and A6). These trends also held for ACLY-α/β (Fig. A8).
Over multiple SE experimental runs, we observed some variability among the ACLY-FL
distributions (FIG. A9). By its nature, SE provides a global average molecular weight of all of the
species in a protein solution, so this approach could have masked the presence of an equilibrium
among different protein subpopulations. One possible explanation for this range could be
multiple species in the solution, perhaps even an equilibrium of different oligomeric states.

Figure M5. The ACLY CSHD is necessary and sufficient for ACLY
tetramerization. Log-linearized radial distribution of SE data
obtained through Absorbance280nm optics for samples at 0.4
mgmL-1, centrifuged for 24 hrs. at 9000 rpm. The natural log of
the experimental data (∆) were compared to simulated
monomer (grey) to tetramer (dark blue) distributions for ideal
globular proteins corresponding to multiples of the monomer
molar mass of the corresponding ACLY species. Single
representative result of at least two independent experiments,
n=1 each experiment.
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To assess if the solution contained multiple ACLY species, we employed dynamic light scattering
(DLS). DLS is a fast and non-destructive analysis of protein tumbling in solution131. The sample
was monodisperse, i.e., DLS did not detect any sizeable populations of soluble aggregates or
breakdown products in the solution that might not have separated during SEC. For
completeness, we tested the light scattering of a range of ACLY-FL concentrations. We applied a
linear regression analysis to define the hydrodynamic radius at infinite dilution (Rhτ) as 8.78 ±
0.326 nm and the diffusion coefficient (Dτ) at infinite dilution as 1.55 ± 0.08 cm2s-1 (Fig. A10 and
Table A2).
DLS is good for detecting large differences in particle size (>1 nm). However, it is not powerful
enough to resolve multimers that are within that size range. For this reason, we employed
another form of analytical centrifugation, called sedimentation velocity (SV). SV is able to
resolve single-kiloDalton differences among species, and so is useful for the detection of
equilibria among multiple species under cell-free solution conditions132. Our SV experiments
confirmed that ACLY-FL was predominantly a single species in solution with an average,

Figure M6. ACLY-FL and truncation
constructs are single species in
solution. Sedimentation velocity of
0.3 mgmL-1 protein at 42000 rpm
and 4°C across at least two
independent experiments, n=1 each.
ACLY-FL (Three Shades of Grey),
ACLY-Nterm 1 (shades of red), and
ACLY-Cterm 4 (shades of blue).
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standardized sedimentation coefficient (s20,w) of 14.6 ± 0.329 S (Fig. M6 and Table A3).
We also returned to our SE results for more complex modeling of the data. We interrogated our
data with several equilibrium models, ranging from monomer-tetramer to monomer-dimertetramer equilibria (Table A4). Upon further analysis, the ACLY-FL distribution also fit to a dimertetramer equilibrium model, with a predicted Kd of 4.71 µM, although with a higher goodness of
fit (χ2). The equilibration between dimeric and tetrameric states could be another means of
regulating ACLY. Citrate synthase dissociation is a powerful regulatory mechanism that responds
to protein levels, the local pH, and the local ionic environment to toggle citrate synthase
between a dimeric active state and a monomeric inactive state, with a Kd of 0.2 µM133. During
periods of high glycolytic flux, cellular ACLY levels also increase several fold134. Therefore, ACLY
might be controlled by a similar concentration-dependent switch, offering a new framework for
regulating ACLY levels in vivo.
Lastly, we looked at the ability of ACLY to form multimers a more complete biological context by
co-expressing ACLY fused to different epitopes in HEK293T cells. We found that the
heterologous constructs could complex together and precipitate one another (Fig. M7)135. We
saw that FLAG-ACLY could be detected after pulldown with Myc-ACLY. This finding served as
confirmation that human ACLY also forms a multimer in the cellular environment. Although this
was not proof of tetramerization in cells, it suggested that our in vitro cell-free studies were
informative of ACLY behavior in vivo.
Overall, our investigation revealed that full-length ACLY is a tetramer in solution with some
predisposition to dissociate into a dimer.
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Figure M7. Western blotting
analysis of ectopic ACLY-FL Co-IP
in HEK293T cells.
Immunoprecipitation of ACLY-FL
with C-terminal Myc epitope,
tested with anti-FLAG for
evidence of association, with
detection by anti-Myc as
confirmation of pulldown.
Ectopic expression was
confirmed through blotting of the
pulldown inputs. The levels of βactin in the input were used a
loading control.
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Human ACLY multimerization is mediated by the ACLY C-terminal citrate synthase
homology domain
Size-exclusion chromatography of our ACLY truncation constructs confirmed that the loss of the
CSHD collapsed the enzyme complex to a stable monomeric state. We observed that all of our
ASHD constructs were monomeric and that all of our CSHD constructs were multimeric (Fig.
M2C). When we produced the CSHD alone we observed the migration of the purified species at
a significantly earlier retention volume than expected for the 34 kDa CSHD monomer. Thus, we
define ACLY residues 820-1101 the minimum essential region for the formation of a protein
multimer.
However, we could not say from the migration profiles whether our ACLY-Cterm constructs
formed the same multimer as the full-length protein. The migration profiles were broad, similar
to the full-length protein. For this reason, we again turned to analytical ultracentrifugation and
light scattering experiments to better characterize the multimeric state of these constructs.
SE analysis confirmed that the CSHD drives ACLY tetramerization. Ideal-species global analysis of
the SE data for ACLY-Nterm 1 and Nterm 2 calculated the global molecular weights as 82 kDa
and 72, respectively. These estimates were close to the expected molecular weight of 93 kDa
and 54. When linearized, these data aligned well to the expected distributions for a single
monomeric state (Fig. M5 and A11). Equally important were the observed molecular weights of
the ACLY C-terminal truncation constructs, which consistently pointed to a tetrameric state (Fig.
M5 and A12; summarized in Table M2). We found that the Cterm 4 construct, with a single
species molecular weight of 138 kDa, was sufficient for tetramerization. Just as with the full-
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length enzyme, these data aligned closest to the expected distribution for a homotetramer. We
took these data to support our observation that the CSHD is sufficient for ACLY multimerization.
Table M1. Molecular weight determination of ACLY-FL by sedimentation equilibrium analytical ultracentrifugation.
Species

Residues

ACLY-FL

1-1101
1-452,
477-1101

ACLY-α/β

X2

Stoichiometry

AU280nm
0.00233

1.19

4

2421

0.00711

2.08

-

Theoretical
molecular
weight

Experimental
molecular
weight

Monte
Carlo
Simulated
Error
(CI=0.95)

Average
root
mean
square
deviation

Da
123801

Da
451965

Da
3281

122500

444127

ACLY-Nterm1

1-820

92758

81797

1337

0.0121

2.25

1

ACLY-Nterm2
ACLY-Cterm1
ACLY-Cterm2
ACLY-Cterm3
ACLY-Cterm4

1-452
426-1101
477-1101
627-1101
820-1101

5353
74590
72610
55648
34390

7210
247109
189671
255229
138255

4010
1267
4511
7058
2281

0.00160
0.00332
0.00417
0/00585
0.00397

1.72
5.53
1.38
2.69
1.56

1
4
3
4
4

We complemented the SE data with DLS and SV of the Nterm 1 and Cterm 4 constructs (Fig. A13
and Table A3). These studies did show some broadness and kurtosis of the distributions, and so
we went back to our SE data to test different equilibrium models for these trends.
As described above, ACLY-FL fit to a dimer-tetramer equilibrium model with a predicted Kd of
4.71 µM. The ACLY-Cterm data could also be fit to a dimer-tetramer equilibrium with a
predicted Kd of 97.7 µM (Table A4). Although Cterm4 fit better to this model than to any other
multi-state equilibrium model, the overall fit was still significantly worse than for the singlespecies model. Therefore, we remain cautious about the accuracy of the Kd values. Neither ACLY
ASHD construct could not be meaningfully fit to any complex equilibrium model.
In the grand tradition of scientific discovery136, we sought to establish the importance of
tetramerization by attempting to break it and observing the result. We tested a dilution series of
ACLY-FL by SEC migration and found no shift in the migration profile down to the detection limit
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of the absorbance detector (Fig. A14). The same held true for SEC of ACLY-Cterm 4 (data not
shown). Our experiments led us to believe that ACLY cannot exist as a monomer. In no
circumstance did we observe the presence of an ACLY-FL or ACLY-Cterm monomeric state. We
aligned the CSHD to citrate synthase and mapped the likely interface to residues 918KDLVSSLTSGLLTIGDRF-936, which in the CS dimer are arranged in a tetrahelical core bundle.
Subsequent structural data supported this prediction, with the CSHD of each subunit
contributing a helix119,127 (see Conclusions below). We designed point mutants of ACLY-FL in this
region, but recombinant expression in E. coli or Sf9 only evidenced ACLY breakdown products
(data not shown).
Together, these data demonstrate that the ACLY CSHD drives ACLY tetramerization. The CSHD
forms the tetramer independently of the ASHD, with great similarity to the structural properties
of CS. This tetramer appears integral to ACLY structural stability.

Multimerization increases the thermal stability of ACLY
One among many advantages of protein self-multimerization is increased structural stability111.
We asked if this were true for ACLY and sought to quantify any conferred advantage through
thermal stability assays.
One method of studying the structural stability of proteins is differential scanning calorimetry
(DSC), a technique that precisely measures the energy released as a macromolecule is heated
and its chemical bonds are broken. DSC analysis revealed that ACLY-FL had a distinct bimodal
profile (Fig. M8 and A6). This held true for ACLY-FL produced in bacteria or Sf9, as well as for the
ACLY-α/β construct. The enzyme underwent two melting transitions, with average melting
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transitions (TM) of 53.8°C (referred to as peak 1) and 69.3°C (referred to as peak 2). The
bimodality made us consider the split origin of the enzyme’s ASH and CSH superdomains,
inviting the idea that these regions were split in terms of structure as well as function.
In contrast to the ACLY-FL melt profile, ACLY-Nterm 1 and ACLY-Cterm 4 had only single
transitions (Fig. M8). These constructs had average TM values of 46.2°C and 73.0°C, respectively
(summarized in Table A5). The latter was particularly high compared to the other constructs,
leading us to reason that the CSHD tetramer was a tight complex with many points of
interaction. This information on its own did not however add much to elucidate the broader
participation of the CSHD in the overall ACLY structure.

Figure M8. The CSHD confers
structural stability. The samples
were assayed at 25 µM.
Representative trace of two
independent experiments, n=1
each, with average TM overlaid.
Scans ran from 10°C-90°C at 60°C
hr-1.

The comparison between the DSC results for ACLY-FL to these truncated constructs presented
new insight into the ACLY structural architecture. The similar TM values of the CHSD and the 2nd
peak of the full-length enzyme suggested that ACLY-FL underwent two distinct unfolding events,
one for each superdomain. The CSHD data best fit to a simultaneous unfolding/dissociation
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model (with the lowest χ2/DF value), as did the ACLY-FL peak 2. Therefore, we propose that the
ACLY-FL peak 1 represents the unfolding of the ASHD.
Of note, The unequal ΔHCAL/ΔHvH ratio of ACLY-FL peak 1 and of ACLY-Nterm 1 suggested some
underlying structural complexity137,138. We speculate that the hidden states hinted at by the
unequal ΔHCAL/ΔHvH ratio might be the separate unfolding of the ATP-grasp and citrate-binding
regions, separated as they are by the bridging, unstructured Domain 5. We were able to better
fit the ACLY-FL peak 1 to a three-state fitting model, with transitions at 53°C and 56°C. However,
we could not do so for ACLY-Nterm 1. DSC analysis with a slower ramp rate did not reveal the
likely underlying transitions. Also, the full-length protein could not be refolded after
denaturation (Fig. A6 and Table A5). This result suggested that the intramolecular interactions
maintaining the various domains of ACLY are stable ones, i.e., we could detect no equilibrium
between different conformations of the enzyme139.
The difference between the melting temperatures of two peaks of ACLY-FL and the individual
melting temperatures of the corresponding truncations might be due to the multimeric context.
The direction of stabilization relative to ACLY-FL provided a clue that the ACLY N- and C-termini
interacted with one another. The ASH superdomain is strongly stabilized by the self-association;
the superdomain gains approximately 8°C of stability when brought into the ACLY tetramer. We
would not expect such a change were the ASH superdomain a self-satisfied structural unit,
isolated from the CSHD. In contrast, the full enzyme appears to suffer some sacrifice of the
stability of the CSHD. This domain appears approximately 4°C less stable in the context of the
full complex (Table A5). That we see this decrease suggests that CSHD might provide more than
an inert tether to the other ACLY subunits. However, the communication between the N- and C32

termini is not so strong as to produce a single melting event for the ACLY complex. Therefore,
the two superdomains might have only a few points of contact.
This conclusion was supported by the SEC of ACLY-Nterm 1 mixed with excess ACLY-Cterm 4.
This assay demonstrated that the two fragments elute closer to each other than when ACLYNterm 1 and ACLY-Cterm 4 are run separately (Fig. A15). We conclude that in the absence of an
intramolecular tether, the two domains might still weakly interact. We next asked what the
mechanism of this interaction might be, and what might be the functional consequence of
crosstalk between the N- and C-termini.
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Functional Studies of the ACLY Superdomains
ACLY enzymatic activity requires tethered N- and C-terminal cooperation
Prior to the solution of the ACLY holoenzyme structure, the models of ACLY function were
guided by the ACLY homology to acyl-CoA synthetases, with little known about the contribution
of the CSHD. The SCS-homology model for ACLY function suggested that the ACLY-Nterm 1
construct should be capable of binding all ACLY cofactors and catalyzing the formation of acetylCoA and oxaloacetate. Contrary to this model, we observed that the loss of the CSHD completely
abrogated acetyl-CoA production (FIG. M9).

Figure M9. ACLY needs the
CSHD for enzymatic activity.
Enzymatic activity of ACLY-FL,
Nterm 1, and Cterm 4
constructs. The constructs were
tested separately at 20 nM
each by MDH-coupled assay. All
experiments were carried out
under cell-free conditions with
three independent experiments,
n=6 replicates each. n.s. not
significant **** p ≤ 0.0001. The
velocity is expressed in terms of
µM of substrate turned over per
minute per mol of enzyme.

This observation offered the possibility that the CSHD contacted the N-terminus to directly
interact with cofactors as a part of the molecular mechanism of turnover. In order to test this
hypothesis, we assayed if ACLY-Cterm 4 added in trans could restore ACLY N-terminus activity.
We observed that incubation of ACLY-Nterm 1 with up to 10-fold molar excess of ACLY-Cterm 4
did not rescue catalysis. We also carried out this experiment with a longer construct of the ACLY
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C-terminus, ACLY-Cterm 2, as a control for construct-design artifacts. We observed no rescue of
activity in trans (Fig. A16).
Consistent with the DSC data, our titration experiments suggested that the CSHD regulated the
N-terminal domain in cis. We were surprised by this result given that ancestral ACLY operates as
a tetramer of α/β dimers, which complex together to effect Ac-CoA production, as
demonstrated in the literature112,119 and in our work (Figs. M2, M3, A5, A8; Tables M2 and A1).
We reasoned that the α/β subunits must come together shortly after translation, before the
ACLY α subunit forms the tetramer to the exclusion of the β subunit. Alternatively, the residues
477-820 in our Nterm 1 construct might occupy the interface within residues 1-452 and so
prevent intermolecular interaction with the Cterm constructs. It is possible that organisms that
use α/β instead of a single-polypeptide might use this phenomenon to limit functional ACLY
production. Alas, further investigation on this point is beyond the scope of the study.
We considered the possibility that the ASHD was solely-responsible for catalysis, only using the
CSHD to come into proximity with the ASHD of another subunit. To get at this question, we
designed and expressed fusion constructs of the ASH with variants of the leucine zipper
sequence of Gcn4 (Fig. A17; Table A6). Depending on the sequence used, these molecular
zippers form obligate dimers, trimers, or tetramers without any known catalytic
functionality140,141. We were able to express these chimeric constructs, albeit at low levels.
Importantly, there was absolutely no rescue of enzymatic activity (Fig. M10). This supported the
idea that the ASHD needed the CSHD for catalysis, not just structural integrity.
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Figure M10. Heterologous
multimerization does not rescue ASHD
activity. The ACLY-Nterm-Gcn4
chimeric constructs were tested at 1
µM by MDH-coupled assay; result of
one experiment, n=3 replicates. n.s.
not significant, **** p ≤ 0.0001. The
velocity is expressed in terms of µM of
substrate turned over per minute per
mol of enzyme.

Negative results being inherently vexatious, we could not rule out these results as artifacts of
our heterologous system. For instance, it was possible that catalysis did not occur because the
ASH domains of the chimeras were not oriented with one another the same way as in wild-type
ACLY. For this reason, we carried out the inverse of this experiment. We either mixed or coexpressed ACLY-FL with excess ACLY-Cterm 4, to naturally dilute the full-length subunits away
from one another until there was only one ASHD per complex. Unfortunately, ACLY-FL did not
stay together with Cterm 4 when the two were separately purified and then co-incubated (Fig.
A19). Most likely, the CSHD complex is inviolable once formed. However, we were able to form a
mixed complex when we co-expressed the constructs in the bacteria (Fig. A20). We observed a
shift in the SEC retention profile on a superdex 200 increase chromatography column. We tested
the activities of the fractionated eluates and found a significant decrease in activity per mg of
protein (Fig M11). Notably, this change was a decrease in activity but not a full abrogation. We
reasoned that one ASHD subunit was still able to turn over substrate without any other ASHD
subunits so long as it could still interact with the CSHD.

36

Figure M11. The ACLY monomers
function independently within the
tetrameric complex. Enzymecoupled activity of Co-expression
and co-purification of ACLY-FL
with ACLY-Cterm 4. The SEC eluate
was tested at different retention
volume positions by MDH-coupled
activity assay (one experiment,
n=4 replicates). The velocity is
expressed in terms of µM of
substrate turned over per minute
per mg of protein.

When the structure of the full tetramer became available, the picture was entirely consistent
with this hypothesis. It was clear that the ASH superdomains of the subunits were in contact
with a small patch of the CSHD while oriented far and away from the ASH superdomains of the
other subunits, with little possibility of cooperation.
We next wondered if the cooperation of the ASHD and CSHD regulated catalysis through the
binding of the enzyme cofactors.
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The ACLY N-terminus optimally binds CoA in the context of the full enzyme
The crystal structures of eubacterial CS with citrate and CoA define an essential histidine and
aspartate in the CS active site to stabilize the citryl-CoA enolate intermediate107, as well as
several others that contact the adenine and pantetheine moieties108. Some, but not all, of these
same residues are present in the ACLY CSHD. We again turned to thermal stabilization in order
to understand if the CSHD could directly contact the reaction participants.
We initially used differential scanning fluorimetry (DSF)142 to rapidly assay the potential
interaction of our ACLY N- and C-terminal constructs with CoA, citrate, and MgATP in different
combinations at 20-fold molar excess (Fig M12). ACLY-FL was significantly stabilized by every
cofactor except for the OAA product. For example, the addition of MgATP produced a shift of
3.87°C, citrate produced a shift of 2.19°C, and CoA produced a shift of 3.03°C. These effects
were additive as more of the reaction components were combined (summarized in Table A7).
For ACLY-Nterm 1, we observed significant stabilization by ATP (5.17°C) and citrate (4.39°C). On
the other hand, CoA had no significant stabilizing effect (-2.07°C). This result argued against the
idea that all substrate-binding and reaction chemistry would occur in the ASHD. More surprising
still was that the CSHD did not evidence any apparent stabilization by any cofactor combination.
Neither the SCS nor CS models aptly predicted the mode of cofactor binding. Yet, it appeared
that CoA binding was the crux of the issue. We postulated that the ASH and CSH domains must
be brought together in the full-length complex to create a CoA binding site at the domain
interface.
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Figure M12. The CSHD is necessary for ACLY CoA-binding. Differential Scanning Fluorimetry assay of ACLY
truncation constructs. Each construct was analyzed at 0.1 mgmL -1 with saturating concentrations of
substrates or products against buffer. Results plotted as thermal stability increase upon cofactor addition.
Summary of four independent experiments, n=8 replicates each. Difference from WT: n.s. not significant, * p
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. All unlabeled measurements are n.s.
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To more sensitively probe the effect of CoA binding to ACLY, we carried out a DSC analysis of
ACLY-FL, ACLY-Nterm 1 and ACLY-Cterm 4 in the presence and absence of CoA, again at 20-fold
molar excess. We observed a statistically-significant shift for ACLY-FL upon incubation with CoA
(1.0°C), whereas the addition of CoA again did not have an effect on the thermal stabilities of
the ASHD or CSHD alone (Fig. M13; Table A5). Interestingly, the addition of CoA only affected
the stabilization of ACLY-FL peak 1. CoA also sharpened the peak 1 melt transition, producing a
better fit of the data. Going back to our previous conclusion that the ACLY-FL peak 1 profile
reflects the ASHD in the full enzyme, we conclude that the peak 1 shift with CoA is indicative of
the ACLY N-terminus binding to CoA only when in the context of the intact protein.

Figure M13. CoA can only bind in
the context of the ACLY tetramer.
Differential scanning calorimetry
of ACLY full-length and
truncations. The samples were
assayed at 25 µM with or without
CoA at 500 µM. Representative
trace of at least two independent
experiments, n=1 each, with
average TM overlaid. Scans were
run from 10°C-90°C at 60°C hr-1.
Difference from apo state: n.s. not
significant, * p ≤ 0.05.
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CHAPTER 3: DISCUSSION
Summary
Our results elucidate the molecular underpinnings of ACLY tetramerization. We demonstrate
that tetramerization requires the evolutionarily-conserved C-terminal citrate synthase homology
domain. Moreover, we show that ACLY cannot function without the CSHD. We define the CSHD
as necessary for CoA binding through coordination with the ACLY SCS superdomain. This is a
surprising finding for two reasons. First, the CSHD is a tetramer, not a dimer like citrate
synthase. Second, although both the N-terminal and C-terminal superdomains have consensus
sequences for binding CoA, neither is able to coordinate CoA without the other. Clearly, multiple
residues in the CSHD directly contribute to catalysis through cofactor binding.

Support for our model of CSHD function
When this project first began, the model of the ACLY structure was a synthesis of partial crystal
structures of the monomeric N-terminal domain. These structures conformed to the canonical
model of an SCS-like molecular mechanism of cofactor binding109,118,143. These structures
captured the ATP-binding and citrate binding domains109,143, as well as the histidine of the active
site118. These crystallographic models suggested that the enzyme ATP-grasp domains 4 and 5
bind ATP with Mg2+ and rearrange to autophosphorylate the catalytic histidine 760 (Eq. 1), which
then complexes with citrate (Eq. 2) at the junction of two power-helices from domains 2 and
5109,118. In these structures, citrate is locked into its pro-S conformation by loops in domains 1
and 5. The 343-348 loop forms extensive backbone contacts to the molecule, while the side
chains of residues R379, and T348 also form direct contacts. This was consistent with our citratebinding data. Yet, significant gaps remained, literally and metaphorically, in these models.
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Coincident with our work, new structural solutions of the ACLY complex confirmed our findings
about tetramerization and superdomain interactions. ACLY is clearly a tetramer with D2
symmetry (Fig. MXA-B). In structural solutions of the holoenzyme, the C-terminal
tetramerization occurs at a central tetrahelical core, with an asymmetric dimer of dimers127. The
CSHD tetramer closely resembled the citrate synthase core bundle (Fig. MXC). It appears as if
the ACLY CSHD evolved to eventually displace one helix (α5 or α10) from each CS subunit in
order to adopt the same structure as CS.
This model also supported our biochemical results for CoA binding. Wei et al. modeled their
human structure with that of chicken citrate synthase in complex with carbomethoxy-CoA,
placing the CoA in the ACLY CSHD. Initially this result did not concur with our DSF or DSC data, as
these techniques did not support the isolated interaction of the CSHD with CoA. Yet, upon
further analysis of the carbomethoxy-CoA overlay, it appeared that the N-terminus was also
contributing to CoA-binding. However, Verschueren et al. also put forward structures of both
full-length ACLY or just the ACLY CSHD as tetramers with phosphate, citrate, and CoA119.
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Figure M14. Structural solutions confirm that ACLY forms a tetramer through the CSHD. (A) Domain map of
ACLY according to the N-acyl synthetase homology model. (B) Left: Cryo-EM solution of ACLY (PDB = 6O0H),
with subunit 1 labeled by domain, as in panel A: ATP-Grasp 1, ATP-Grasp 2, Flexible bridge, N-acyl homology
citrate-binding domain, N-acyl homology CoA-binding domain, and CSHD. Right: Thermus thermophilus citrate
synthase dimer (PDB = 1I0M) (C) Left: Zoom view of the CSHD helical core (180° rotation), with labeling of the
α29 tetrahelical core and the supportive α28 outer shell. Right: Zoom view of the citrate synthase dimer
interface with comparable orientation to the CSHD. Middle: Alignment by PyMOL of the CSHD with citrate
synthase to highlight the evolutionary displacement of one helix per subunit.
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There is clearly cooperativity between the ASHD and CSHD; phosphate and citrate bind at the
ASHD while CoA is jointly coordinated at the interface of the ASHD with the CSHD from two
other subunits (Fig M15). These structures showed canonical contacts between citrate and the
enzyme at the 306-312 and 343-348 loops, as well as His760. Yet, these structures also showed
CoA binding occurring between those loops and loop 966-984 of the CSHD of the antiparallel
subunit. This model agrees with our biochemical data that the N- and C-termini need one
another for CoA binding and must be properly oriented for catalysis to
occur.

Figure M15. CoA binds at the ASHD-CSHD interface. Crystallographic solution of ACLY (PDB = 6HXH) with phosphate,
citrate, and CoA as a mimic of the citryl-CoA intermediate. The adenine ring of CoA is within bonding distance of the
CSHD of subunits 2 and 3, while the reactive thiol is positioned toward citrate at the junction of several domains of
ACLY subunit 1. The ACLY monomers are colored as in Fig. M14.
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Future Directions
We have made significant progress in understanding the how of ACLY function. We identify the
role of the tetrameric state in catalysis. Yet, these results were at times surprising and
contradictory. For instance, our SE data suggest an equilibrium between dimeric and tetrameric
states. Such an equilibrium is not outside the realm of probability, as it is present in a close
evolutionary partner. Yet, we observed no experimental evidence by DLS or SV for a dimeric
state. It remains to be seen if we can find conditions in vitro or in vivo that might produce an
ACLY dimer. In the comparison to CS, we see that each subunit of ACLY contributes one helix to
the core bundle that keeps the tetramer together. Possibly, we might mutate the helices to
break the pair along one axis, while creating disulfide crosslinks to staple a helix pair in the other
axis. However, the picture of CoA binding suggests that the CSHD from multiple subunits are
actually necessary for function. Therefore, we doubt that a dimer pair, laterally or diagonally,
would still retain full functionality.
Additionally, the residues that mediate CoA binding remain unverified. Although the residues
that mediate citrate binding have been biochemically studied109,118, the same is not true of the
CoA binding site proposed above. Yet, it is necessary in order to understand the residues that
would participate in binding potential CoA-analog inhibitors. Recently, a small-molecule
inhibitor, bempedoic acid, has proven efficacious at inhibiting ACLY function, and consequently
acetyl-CoA levels, ultimately decreasing dyslipidemia and atherosclerotic phenotypes88,144. It is
now apparent that bempedoic acid is the prodrug form, which is condensed by very-long chain
acyl-CoA synthetase in the liver to a CoA adduct (bempedoic-CoA)79. This adduct likely occupies
the CoA-binding site at the ASHD-CSHD interface, acting as a competitive inhibitor of the
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enzyme. The development of this drug is a significant advance for medicinal targeting of ACLYdependent disorders. A better mechanistic understanding of its interaction with ACLY would
open up further refinement and improvement, hopefully to maintain the potency of inhibition
while preventing off-target effects on other acyl-CoA binding proteins.
We also provide evidence for a second general base in the reaction mechanism. However, the
general-base residue is still not known. The structure by Verschueren et al. proposes aspartate
1026 as the general base107,108. Others have proposed the participation of glutamate 599 in the
binding of CoA109. Therefore, further study is necessary to describe the molecular process
underlying this activity profile. We propose point mutagenesis at these residues to study the
effect on function. In defining the catalytic base, we would complete the picture of the reaction
mechanism. Moreover, we could then ask if and how ACLY function could be modulated by its
local chemical environment, as is the case with citrate synthase133.
To address these questions and validate the structural models of cofactor binding and turnover,
we propose to mutate residues E599, H975, and D1026 to alanines or residues of opposite
polarity to study this pocket. We would then test the activity of the mutant enzymes by MDH
assay to assay the effect on kcat and KM with variable CoA as a readout for the contribution of
those residues for function. We would also carry out DSC analyses with the mutants, with the
expectation that point mutant would have a weaker TM shift with CoA. ITC experiments would
be ideal for disambiguating the free energy contribution of each residue for cofactor interaction.
However, ITC experiments with ACLY to date have proven difficult. We also propose to study
these mutants in cells, through the quantification of cell proliferation and lipid synthesis.
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Lastly, we wonder at the relationship between the ACLY tetrameric complex, cofactor binding,
and interactions with other cellular factors. The control of ACLY protein levels is a convenient
and powerful means of rapidly affecting cellular acetyl-CoA levels. Various tissue types vary both
ACLY and Ac-CoA to effect metabolic reprogramming145. Various signaling pathways include
ACLY activation as a part of stimulating glucose consumption and growth, including insulin and
EGF signaling54. Insulin can trigger a signal cascade down to the Akt kinase43,84,146, which
phosphorylates ACLY and increases ACLY activity through an unknown mechanism147. The
increase in ACLY activity alters histone acetylation patterns, affecting the expression of a
plethora of genes148. Histone acetylation in particular is dependent on glucose149. The silencing
of ACLY significantly decreases global histone acetylation. Moreover, this silencing cannot be
entirely rescued with acetate, which is converted to Ac-CoA through an independent pathway42.
How ACLY affects gene expression is not clear. It could be an indirect mode of influence; ACLY
could increase gene expression globally by increasing global nucleocytosolic Ac-CoA levels. Yet,
we know that particular loci are sensitive to stimulation by glucose. ACLY could have a direct
mode of influence on those loci. We know that upon stimulation, ACLY translocates to the cell
nucleus150. Yet, ACLY does not have an obvious nuclear localization signal. Currently there is only
indirect evidence of ACLY interaction with other proteins. We speculate that ACLY may interact
with nuclear factors to move to the nucleus, potentially forming molecular machines to increase
the local acetyl-CoA concentration for downstream use, such as protein acetylation.
We propose to study these potential interactions through in vitro pulldowns and migration
studies of recombinant ACLY with recombinant ε- or Nα-acetyltransferases, such as P300/CBP
Associated Factor (PCAF) and N-Acetyltransferase A (NATA), respectively. We also propose
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unbiased screens for ACLY protein partners through pulldowns of biotin-tagged ACLY with
cytosolic and nuclear lysate fractions, followed by mass spectroscopy analysis of protein
identities. The epitope-ACLY could be produced recombinantly and later used as bait or
expressed transiently in the cells, so that the protein complexes may form in the appropriate cell
compartments or cell states. We hope that identifying and characterizing ACLY interactions with
other cellular actors will inform on the broader in vivo context in which ACLY operates, and the
molecular mechanisms by which it is regulated by other proteins.
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Précis
Our findings present novel opportunities for ACLY regulation. We connect the evolutionary
relationship between ACLY and the CS superfamily to a molecular framework for ACLY function.
Our light-scattering and analytical ultracentrifugation experiments show that human ACLY is a
stable and consistent homotetramer. Our activity and substrate-binding assays lead us to
conclude that the CSHD is necessary but not sufficient for the binding of CoA and ultimately the
production of acetyl-CoA. Contrary to previous models, we demonstrate that ACLY has adapted
the CSHD for a more nuanced role as a facilitator for the activity of the N-terminal SCS
superdomain. DSF and DSC analyses indicate that the two major regions of the enzyme
communicate with one-another. Their interaction increases the stability of the SCS superdomain
and forms the CoA-binding site. To date, we have been unable to isolate stable, monomeric
ACLY through point mutagenesis of the CSHD. It stands to reason that structural destabilization
through the loss of tetramerization would have severe deleterious effects on catalysis. Our
findings also explore the possibility that ACLY modulates gene expression directly through
protein-protein interactions. However, we have only tenuous proof of such an interaction in our
cell-free system. In summary, we open the door to a new paradigm for thinking about the
various signals that elevate or abrogate ACLY levels in healthy and unhealthy systems.

Significance to human health
ACLY is a major node in the transduction of insulin signaling to changes in gene expression. It
unites the CoA and citrate metabolic pathways, both of which serve multiple, indispensable
cellular needs. It is a highly-prized target for metabolic disease therapy, including therapies for
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atherosclerosis, hypercholesterolemia, and also oncogenesis55,151. In the latter case, the
dependence of tumors on glucose for energy makes ACLY inhibition especially appealing. ACLY
knockdown can drastically decrease cancer cell proliferation without significantly affecting
nearby healthy tissue 152. ACLY might also be a target for anti-aging studies, as decreased
nucleocytosolic acetyl-CoA levels and ACLY inhibition might delay the onset of age-related
decline73,74.
While ACLY has been the focus of myriad clinical studies66,80, many of these efforts have stalled.
There are few promising small-molecule ACLY inhibitors. Therefore, there exists a clear need for
a better understanding of the biochemistry of the enzyme. Although a great deal of effort has
gone into understanding the signaling cascades and post-translational modifications that tune
ACLY function in the cell79, limited knowledge about the molecular basis of ACLY function has
held back the development of ACLY therapeutic treatments. We propose that the ACLY CSHD, as
well as the active site at the ASHD-CSHD interface, might be potent and specific target for
rational drug design. Together, these studies highlight a novel role of the C-terminal CSHD in
ACLY function.

Significance to evolutionary understanding
The importance of ACLY in cell metabolism is evident in its long evolutionary pedigree. The
enzyme arose early in eukaryotic evolution from the last eukaryotic common ancestor (LECA),
followed by a swift spread across evolutionary space in distinct monophyletic lineages of singlepolypeptide or heterodimeric-polypeptide ACLY-α/β states123. Regardless of the forms that the
myriad ACLY orthologs have taken, the amino-acyl sequences and secondary structures of these
forms have remained widely conserved (Fig. A2).
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We posit that a genetic rearrangement event, early in the evolution of citrate utilization for
acetyl-CoA production, created the link between ancestral SCS and CS. This event conferred not
only additional size to the protein, but also the ability to oligomerize, both of which offer
numerous advantages153. This fusion provided a ready means of increasing enzyme stability and
acetyl-CoA output that has endured across millions of years of evolution123. The first steps of the
ACLY reaction mechanism, including nucleotide- and acyl-binding, are very similar to those of
the acyl-CoA synthetase superfamily members125,154. Ancient ACLY orthologs have even retained
the independent functions of the SCS and CS superdomains. In the prokaryote Chlorobium
limicola, the CSHD is capable of binding cofactors at both the ASHD and CSHD, even going so far
as to catalyze both the forward and reverse Claisen reactions that make or break citrylCoA102,119. Our thermal stability analysis of the ACLY superdomains leads to the notion that ACLY
might have first used the multimerization for stabilization of the ASHD. It is possible that ACLY
began as an acetyl-CoA synthase that fused together with CS for added stability and increased
acetyl-CoA production. Over millions of years, eukaryotes have developed a taste for glucose
over other metabolites, such as acetate. As this occurred, there was a concurrent shift from
reductive to oxidative respiration and a change in the availability of cytosolic citrate. We
speculate that during this shift, the eukaryotes might have prioritized ACLY for cytosolic Ac-CoA
production over citrate synthesis, such as for the synthesis of lipids or for epigenetic signaling.
ACLY might have lost its independent CS function, freeing up the residues in the former CS active
site for use in Ac-CoA synthesis and for the regulation of the enzyme’s activity.
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As we learn more about the ACLY mechanism, we gain new understanding of its origins. With it,
we learn more about an enduring aspect of eukaryotic biology. We hope that insight builds on
itself to add to our collective knowledge of ourselves and the world around us.
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APPENDIX
Supplemental Figures

Figure A1. Catalysis involves a multi-step reaction mechanism, with several intermediates. Reaction substrates
are boxed in blue, reaction intermediates are in parentheses, and reaction products are boxed in purple.
Electron movement represented by dashed red arrows. Reaction rate constants and KM values are from the
experimental data in Table M1 and from Fan et al.89
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Figure A2. ACLY is evolutionarily well conserved. (A) Domain map. (B) Alignment to orthologous βsubunits. (C) Alignment to orthologous α-subunits. Residues are color coded as hydrophobic, basic,
acidic, polar, cysteines, glycines, and prolines.
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Figure A3. The
ACLY protein
sequence is
similar to acylCoA synthetases
and citrate
synthases. (A)
Comparison of
ACLY to SCS beta
subunits.
Secondary
structure taken
from PDB =
5TDE.
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Figure A3 cont.
(B) Comparison
of ACLY to SCS
alpha subunits.
Secondary
structure taken
from PDB =
5TDE.
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Figure A3 cont.
(C) Comparison
of ACLY to CS.
Secondary
structure from
JPRED model
and PDB =
6O0H.
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Figure A4. ACLY has several points of backbone instability. (A) DISOPRED115 prediction of ACLY intramolecular
instability. (B) Analysis of ACLY fragmentation by mass spectroscopy. Top: LC-MS/MS peptide coverage summary of
ACLY-FL; Middle: LC-MS/MS peptide coverage summary of 80 kDa fragment; Bottom: LC-MS/MS peptide coverage
summary of ACLY 50 kDa fragment.
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Figure A5. Recombinant ACLY FL and ACLY-α/β behave consistently across expression systems. (A) SEC migration
profile of all constructs on superose 6 increase column. (B) SDS-PAGE (12% acrylamide) of samples after SEC.
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Figure A6. Recombinant ACLY FL and ACLY-α/β have similar thermal stabilities. Differential scanning calorimetry assay
of ACLY full-length and ACLY-α/β. The samples were assayed at 5 µM. Scans were run from 10°C-90°C at 60°C hr-1 or
30°C hr-1 as indicated.
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Figure A7. E. coli ACLYFL is a tetramer by
sedimentation
equilibrium analysis.
(Top) Raw distribution
of A280 data for the 0.4
mgmL-1 sample at 6000
(□), 9000 (□), 12000
(□), and 16000 (□) rpm
across the radius of the
sedimentation
equilibrium cell. The
best-fit line of an idealspecies model is
overlaid. (Middle)
Residuals of the fit of
the real data to the
ideal model. (Bottom)
Linearization of 9000
rpm data. The natural
log of the experimental
data (∆) is taken and
compared to simulated
distributions of an ideal
globular protein of
monomeric-tetrameric
molecular weights.
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Figure A8. E. coli ACLYα/β is a tetramer by
sedimentation
equilibrium analysis.
(Top) Raw distribution
of A280 data for the 0.4
mgmL-1 sample at
6000 (□), 9000 (□),
12000 (□), and 16000
(□) rpm across the
radius of the
sedimentation
equilibrium cell. The
best-fit line of an idealspecies model is
overlaid. (Middle)
Residuals of the fit of
the real data to the
ideal model. (Bottom)
Linearization of 9000
rpm data. The natural
log of the
experimental data (∆)
is taken and compared
to simulated
distributions of an
ideal globular protein
of monomerictetrameric molecular
weights.
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Figure A9. ACLY-FL might exist in an equilibrium of states in solution. Linearized radial distribution of all ACLY-FL SE
speeds and concentrations. The natural log of the experimental data for every run. The natural log of the
experimental data for every run (∆, different shades) were compared to simulated monomer (grey) to tetramer
(dark blue) distributions for ideal globular proteins corresponding to multiples of the monomer molar mass of the
corresponding ACLY species. Summary of two independent experiments, n=1 replicate of each condition per
experiment.
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Figure A10. The ACLY-FL
multimer is consistently
monodisperse across a
concentration range (shades of
blue) by dynamic light
scattering. (Top) Volume
distribution of hydrodynamic
radii (Rh) of ACLY-FL at 3.3°C
across two independent
experiments, n=6 replicates
each. The average distribution
(dashed) is overlaid onto the
individual distributions (solid).
(Middle) Correlograms of
replicates as an indicator of
sample quality and complexity.
The nonlinear fit calculated by
SEDFIT (dashed) is overlaid
onto the individual distributions
(solid). (Bottom) Distribution of
hydrodynamic radii, with fit line
of linear regression analysis
(dashed).

64

Figure A11. ACLY-Nterm 1 is a
monomer by sedimentation
equilibrium analysis. (Top)
Raw distribution of A280 data
for the 0.4 mgmL-1 sample at
6000 (□), 9000 (□), 12000
(□), and 16000 (□) rpm
across the radius of the
sedimentation equilibrium
cell. The best-fit line of an
ideal-species model is
overlaid. (Middle) Residuals
of the fit of the real data to
the ideal model. (Bottom)
Linearization of 9000 rpm
data. The natural log of the
experimental data (∆) is
taken and compared to
simulated distributions of an
ideal globular protein of
monomeric-tetrameric
molecular weights.

65

Figure A12. ACLY-Cterm 4 is a
tetramer by sedimentation
equilibrium analysis. (Top)
Raw distribution of A280 data
for the 0.4 mgmL-1 sample at
6000 (□), 9000 (□), 12000
(□), and 16000 (□) rpm
across the radius of the
sedimentation equilibrium
cell. The best-fit line of an
ideal-species model is
overlaid. (Middle) Residuals
of the fit of the real data to
the ideal model. (Bottom)
Linearization of 9000 rpm
data. The natural log of the
experimental data (∆) is
taken and compared to
simulated distributions of an
ideal globular protein of
monomeric-tetrameric
molecular weights.
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Figure A13. ACLY-Nterm 1
and ACLY-Cterm 4 are
monodisperse in solution by
dynamic light scattering.
(Top) Volume distribution of
hydrodynamic radii (Rh) of
ACLY constructs at 8 µM and
3.3°C across at least two
independent experiments,
n=6 replicates each. The
average distribution (dashed)
is overlaid onto the individual
distributions (solid). (Middle)
Correlograms of replicates as
an indicator of sample quality
and complexity. The
nonlinear fit calculated by
SEDFIT (dashed) is overlaid
onto the individual
distributions (solid). (Bottom)
Distribution of hydrodynamic
radii across tested
concentrations.
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Figure A14. ACLY-FL stays a tetramer down to the low nanomolar range. (A) Size-exclusion chromatography of ACLY-FL. E. coli
ACLY-FL was repeatedly run on superose 6 increase column. The eluate at 14.5 mL was taken after each run, checked for
concentration, and re-loaded as a 500 µL volume until undetectable by SDS-PAGE. (B) Right: SDS-PAGE (15% acrylamide) of 4th
dilution. Left: SDS-PAGE (15% acrylamide of 5th dilution. All proteins were visualized on the gel by Silver Stain Plus (BioRad).
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Figure A15. The ACLY ASHD and CSHD weakly interact. (A) Size-exclusion chromatography of 5 µM ACLY-Nterm 1 and 20 µM ACLYCterm 4 individually or after 1 hr. co-incubation. Samples run on superdex 200 increase chromatography column. (B) SDS-PAGE of SEC
eluate for each SEC run on 12% Tris-MOPS.

Figure A16. The CSHD cannot activate the ASHD in trans. MDH-coupled enzyme activity assay of ASHD mixed with
excess CSHD: (Top) Supplementation of 20 nM ACLY-Nterm 1 (ACLY residues 1-820) with various concentrations of
ACLY-Cterm 4 (ACLY residues 820-1101), summary of three independent experiments, n=6 replicates each.
(Bottom) Supplementation of 20 nM ACLY-Nterm 1 with various concentrations of ACLY-Cterm 2 (ACLY residues
477-1101), with one experiment, n=3 replicates each. All experiments were carried out under cell-free conditions.
n.s. not significant, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. The velocity is expressed in terms of µM
of substrate turned over per minute per mol of enzyme.
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Figure A17. ASHD activity cannot be rescued by heterologous reconstitution of a dimeric, trimeric, or tetrameric state. Production of
ACLY-Nterm 1 fused to Gcn4 zipper domains: (A) SEC of chimeric constructs after Ni-NTA, on a superdex 200 increase column. (B) SEC
eluates by Bis-Tris (12% acrylamide) SDS-PAGE.

Figure A18. The ACLY tetramer is stable and does not exchange subunits. Mixing experiment of ACLY-FL and ACLYCterm 4. (A) Size- exclusion chromatography of 10 µM ACLY-FL and 100 µM ACLY-Cterm 4 produced separately and
run together on s200 increase column. (B) MDH-coupled activity assay of 20 nM ACLY-FL with supplemental Cterm
4.
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Figure A19. ACLY-FL can form a stable complex with free CSHD during co-expression. (A) Size-exclusion chromatography of ACLY-FL and ACLYCterm 4, on a superdex 200 increase chromatography column, after co-expression in E. coli and co-purification. (B) Bis-Tris (15% acrylamide)
SDS-PAGE of eluates of the SEC of co-expressed ACLY-FL and ACLY-Cterm 4.

Supplemental Tables

Table A1. Michaelis-Menten-Henri steady state parameters of ACLY constructs.
Specie
s

Syst
em

Substrate

[E]

nM

kcat

Lower
95% CI

Upper
95% CI

KM

s-1

Lower
95% CI

Upper
95%
CI

µM

kcat
/KM

VMax

N

µM s-1

mol min-

Goodness
of Fit
(R²)

1

ACLYFL

E.
coli

ACLYFL

Citrate

20

0.902

0.838

0.965

126

85.5

166

0.00718

1.80

38

0.912

Sf9

0.357

0.335

0.379

94.7

73.1

116

0.00377

0.714

24

0.969

ACLYα/β

E.
coli

0.473

0.425

0.522

45.8

26.7

65.0

0.0103

0.947

24

0.904

ACLYFL

E.
coli

118

107

130

18.9

13.0

24.9

6.25

2.34

40

0.898

ACLYFL

Sf9

91.8

85.6

98.0

45.2

33.8

56.5

2.03

1.84

25

0.980

ACLYα/β

E.
coli

86.1

82.3

89.8

11.7

9.64

13.7

7.39

1.72

31

0.975

CoA

20

Table A2. Light scattering results of ACLY-FL concentration series.
Concentration

µM
0.8
1.6
3.2
5
7.3

Hydrodynamic
radius (Rh)

Lower 95% CI

Upper 95% CI

nm

nm

nm

Observed
Diffusion
coefficient (D)
cm2s-1

8.74
8.84
9.66
7.67
9.32

7.86
8.23
6.59
7.46
8.01

9.62
9.44
12.7
7.88
10.6

1.40
1.75
1.40
1.68
2.36

Lower 95% CI

Upper 95% CI

cm2s-1

cm2s-1

1.11
1.62
-0.57
1.08
0.32

1.69
1.87
3.37
2.29
4.39

N

6
6
3
12
6

Table A3. Distributions of ACLY constructs in solution at a single concentration.
Species

ACLY-FL
ACLY-Nterm
ACLY-Cterm

Hydrodynamic
radius (Rh)

Lower 95%
CI

Upper 95%
CI

nm

nm

nm

7.67
3.82
1.68

7.46
3.71
0.673

7.88
3.92
2.68

N

Sedimentation
coefficient (s )
S (10

21
15
17

74

-13

20,w
-1

sec )

14.6
4.96
6.98

Lower 95%
CI
-13

S (10
sec-1)
14.1
4.95
6.74

Upper
95% CI

N

f/f

4
2
4

1.25
1.33
1.06

0

-13

S (10
sec-1)
15.1
4.97
7.22

Table A4. Summary of goodness of fit of ACLY constructs to various equilibrium models.

Species

ACLY-FL

Theoretical
molecular
weight
Da

Da

Da

AU280nm

Ideal

123801

451965

3281

0.00233

1.19

Kd
error

Stoichiometry

µM

µM

Subunits

-

-

4

168

5.27

6.05E-07
2.76E-05

Monomer-Dimer
Monomer-Tetramer

0.00218

516

3.51

Dimer-Tetramer

0.00743

38.9

4.72

3.36E-07

Monomer-Dimer +
Dimer-Tetramer

0.0202

136

563, 0.00

304, 0.00

.00121

2.25

-

-

Monomer-Dimer

92758

0.107

231

23.5

6.13E-04

Monomer-Tetramer

0.108

281

38.5

3.25E-03

Dimer-Tetramer

0.115

394

64.9

8.58E-03

Monomer-Dimer +
Dimer-Tetramer

0.108

231

232, 46800

5.97E-3, 241

81797

34390

138255

1337

2281

1

0.00397

1.56

-

-

Monomer-Dimer

0.0280

81.4

32.7

8.22E-04

Monomer-Tetramer

0.0330

12.8

39.7

5.57E-04

Dimer-Tetramer

0.0178

187

97.7

1.55E-04

Monomer-Dimer +
Dimer-Tetramer

0.0334

68.1

0.00, 0.00

0.00, 0.00

Ideal

ACLYCterm 4

Kd

X2

0.0195

Ideal

ACLYNterm 2

Average
Monte
Experimental
root mean
Carlo Error
molecular weight
square
Analysis
deviation

Model

4

Table A5. Summary of DSC data for ACLY truncations with or without 500 µM CoA.
Species

TM1

SD

Average
ΔHcal/
ΔHvH

SD

°C

Average
ΔHWA
kcal
M

Fulllength +
CoA
N-term
N-term +
CoA
C-term
C-term +
CoA
ACLYFL 30°C
hr-1
ACLY E.
coli
ACLY
Sf9
ACLY
Coexp

SD

TM2

SD

Average
ΔHcal/
ΔHvH

SD

°C

Average
ΔHWA
kcal M

-1

SD

N

-1

54.9

0.16

2.67

0.36

250

4.45

69.6

0.11

0.87

0.35

123

1.04

2

46.2

2.32

1.67

0.82

135

7.82

-

-

-

-

-

-

2

47.8

3.01

3.20

1.89

156

0.56

-

-

-

-

-

-

2

-

-

-

-

-

-

73.0

0.60

0.23

0.11

188

11.52

3

-

-

-

-

-

-

72.9

0.11

0.35

0.02

184

11.15

3

53.7

-

-

229

-

69.5

-

0.97
0.97366255 -

120

-

1

54.0

-

1.86

-

170

-

71.9

-

0.50

-

144

-

1

54.0

-

1.46

-

198

-

69.5

-

0.46

-

122

-

1

53.8

-

1.36

-

141

-

68.1

-

0.14

-

111

-

1

2.43

75

Table A6. Adapted leucine zipper sequences for ACLY-Nterm chimeric constructs141.
Species

Sequence

Obligate Multimeric State

Gcn4-pIL
Gcn4-pII
Gcn4-pLI

RMKQLEDKIEELLSKIYHLENEIARLKKLIGER
RMKQIEDKIEEILSKIYHIENEIARIKKLIGER
RMKQIEDKLEEILSKLYHIENELARIKKLLGER

Dimer
Trimer
Tetramer

Table A7. Differential scanning fluorimetry for ACLY thermal stabilization by cofactors.
ACLY-FL
Mean

Lower
95% CI

ACLY-Nterm 1

Upper 95% N
CI

Mean

ACLY-Cterm 4

Lower
95% CI

Upper
95% CI

N

Mean

Lower
95% CI

Upper
95% CI

N

Apo

0.00

-0.28

0.28

40

0.00

-0.79

0.79

42

0.26

-0.27

0.79

39

Citrate

2.19

1.76

2.61

35

4.39

4.03

4.76

36

0.95

0.35

1.56

30

CoA

3.03

2.70

3.36

34

-2.64

-4.12

-1.15

36

1.66

1.10

2.21

32

Citrate +
CoA

3.48

2.83

4.13

27

4.30

3.86

4.74

29

-0.64

-2.24

0.97

21

-0.16

-0.98

0.65

32

1.73

0.94

2.53

43

0.07

-0.60

0.74

42

Ac-CoA

1.40

0.94

1.86

44

-0.10

-0.85

0.65

44

-0.17

-0.89

0.54

34

AcetonylCoA

2.43

2.21

2.64

24

-0.41

-1.26

0.44

24

1.12

0.46

1.77

23

OAA + AcCoA

3.27

2.57

3.97

18

3.46

2.94

3.98

24

3.48

2.43

4.54

22

MgCl2

3.47

3.14

3.80

28

5.17

4.45

5.88

36

1.69

0.70

2.68

30

ATP

2.13

1.77

2.48

21

2.91

2.45

3.37

24

3.61

2.52

4.70

21

ADP

-0.55

-0.90

-0.19

35

-3.39

-4.37

-2.42

36

0.51

-0.03

1.06

34

MgCl2 +
ATP

3.87

3.66

4.08

31

6.51

4.97

8.06

36

1.77

0.54

3.00

34

MgCl2 +
ADP

6.48

5.71

7.25

35

10.83

9.80

11.87

34

0.87

0.11

1.63

34

MgCl2 +
Citrate

7.02

6.49

7.55

34

11.62

10.47

12.77

36

-0.07

-0.62

0.47

32

MgCl2 +
ATP +
Citrate
MgCl2 +
ATP +
Citrate +
CoA

0.75

0.27

1.24

35

3.65

2.64

4.66

36

0.68

0.28

1.09

34

1.95

1.58

2.32

19

5.93

5.48

6.38

24

2.79

1.84

3.75

23

OAA
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MATERIALS AND METHODOLOGY

Expression and Purification of Recombinant Proteins
The Homo sapiens ACLY isoform 1 (Accession # NM_001096.2) was used in this study. To
generate the plasmid DNA constructs for recombinant protein expression, this sequence was
PCR amplified from human liver cDNA purchased from ATCC (Manassass, VA) with DNA primers
adding a C-terminal 6x histidine tag sequence and EcoRI/SalI cut sites for ligation. The PCR
product was ligated into a custom-engineered pET Duet-1 vector for Escherichia coli expression
or into the pFastBac HT vector (Novagen) for expression in Spodoptera frugiperda (Sf9). ACLY-FL
and ACLY-Cterm constructs expressed equally in both systems, whereas ACLY-Nterm 2 could
only be produced in the Sf9 system after codon optimization by Genscript (Piscataway, NJ). The
DNA constructs were transformed into Rosetta2 (BL21) cells and grown overnight in a Luria
Broth (LB; EMD Millipore, Rockville, MD) culture with appropriate antibiotic at 37°C with 200
rpm orbital shaking. These cultures were used to inoculate 1L cultures of Terrific Broth (TB; EMD
Millipore). The TB cultures were grown with appropriate antibiotic at 37°C with 200 rpm orbital
shaking until reaching an OD600 of 0.8, at which point the temperature was lowered to 25°C,
induced with 0.2-0.5 mM IPTG, and supplemented with 20 mM D-glucose and 0.5% v/v glycerol.
The cultures were grown for 19 hours. The cells were then harvested by centrifugation at 4000
rpm and lysed via sonication in lysis buffer (25 mM Tris-HCl pH 8.8, 200 mM NaCl, 5 mM MgCl2,
5 mM potassium citrate tribasic pH 7.5, 10 mM β-mercaptoethanol, 1 µg/mL lysozyme, 1 µg/mL
DNase I, 100 µg/mL PMSF, and 1X EDTA-free protease inhibitor [Roche, Basel, Switzerland]). The
lysate was clarified by centrifugation at 19000 rpm and purified by Ni-NTA affinity, followed by
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overnight dialysis into low salt buffer (Tris-HCl pH 8.8, 20 mM NaCl, 5 mM MgCl2, 5 mM
potassium citrate tribasic pH 7.5, and 10 mM β-mercaptoethanol). The dialysate was further
purified by HiTrap Q HP (GE Healthcare, Pittsburgh, PA), superdex 200 HiLoad 16/600 (GE
Healthcare), and superose 6 increase 10/300 GL (GE Healthcare) into size-exclusion buffer (25
mM HEPES pH 8.0, 200 mM NaCl, 1 mM DTT). Bio-Rad (Hercules, CA) gel filtration standard was
used for comparison.
Co-migration studies were carried out in size-exclusion buffer with 1 hr. pre-incubation at 4°C.
The samples were run on a superose 6 increase 10/300 GL or a superdex 200 increase 10/300 GL
column (GE Healthcare). SDS-PAGE was carried out using ExpressPlus PAGE 12% or 15% TrisMOPS gels (Genscript) with ProSieve prestained protein ladder (Lonza, Walkersville, MD).
To produce the chimeric constructs of ACLY-Nterm 1 fused to the leucine zipper domains of
yeast Gcn4, we synthesized the DNA sequences through BioBasic. We followed residue T820 of
ACLY by a 3xGS linker and then the appropriate zipper sequence141 (Table A6).
All sequence alignments carried out with CLUSTAL121, using JalView155 for visualization. Further
alignment to SCS and CS family members was done with BLAST120, CLUSTAL121, and ESPript122
tools. Secondary structure was taken from our ACLY-FL structural data and also modeled in silico
by JPRED prediction115.
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Analytical Ultracentrifugation
Sedimentation equilibrium of the recombinant protein was carried out in size-exclusion buffer at
concentrations of 0.2, 0.4, 0.8 mgmL-1 at 4°C in a Beckman Optima XL-I analytical ultracentrifuge
(Beckman Coulter, Palo Alto, CA). Absorbance optics at 280 nm were taken using quartz
windows in six-chamber charcoal centerpiece in an An-60 Ti four-hole rotor (Beckman Coulter)
with 6 hr. scans with a radial step-size of 0.001 (four scans per speed, with three independent
experiments for ACLY-FL and ACLY-Cterm, two experiments for ACLY-Nterm 1). The speeds used
were 6000, 9000, 12000, and 16000 rpm as recommended based the expected monomer and
tetramer molecular weights of the ACLY constructs156,157.
The molecular weights were calculated by global ideal species analysis by SEDPHAT132. The error
associated with the global analysis was determined by Monte-Carlo simulation with 1000
iterations at a confidence level of 0.95. We only analyzed those data between the sample
meniscus (variable) and Absorbance280nm ≤ 1.5 AU, to avoid violating Beer-Lambert linearity
between concentration and light attenuation. Equilibrium fitting was done with strict mass
conservation, rotor stretch correction, as well as sample bottom, baseline, and RI noise fitting.
Goodness of fit was determined by global reduced χ2. The sample parameters of protein partial
specific volume, buffer density, and buffer viscosity were calculated by SEDNTERP158. Protein
molar mass and extinction coefficients were calculated by ExPASy Protparam159.
Sedimentation velocity experiments were carried out in size-exclusion buffer at a concentration
of 0.3 mgmL-1 for all proteins. The experiments were run at 4°C and 42000 rpm, with a radial
step-size of 0.001 and a five-minute delay between scans (200 scans total, two independent
experiments). Only the minimum number of scans were analyzed132, as recommended for the
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maximum molecular weight by DCDT+ version 2.4.3 by John Philo160,161. The data were analyzed
by SEDFIT162 with a continuous c(s20,w) distribution model with mass conservation and a
confidence level (F-ratio) of 0.95, where the frictional ratio (f/f0) was allowed to float. The c(s20,w)
distributions were plotted using Prism v5.1 (GraphPad, La Jolla, CA).

Western Blot Analysis
Protein samples were prepared in 1x Laemmli buffer as standard for SDS-PAGE. Following
electrophoresis, the proteins were transferred in transfer buffer (19 mM Tris-base, 90 mM
glycine, 20% methanol, pH 8.3) into a PVDF membrane (BioRad) in an XCell II Blot Module (Life
Technologies) at 4°C for 2.5 hrs at 300V, 300 mA or overnight at 20V, 300mA. The membrane
was blocked with 3% BSA in TBST (19 mM Tris-base, 137 mM NaCl, 0.05% v/v Tween-20) for 1 hr
with rocking at 4°C. The blot was exposed to primary antibody at 1:1000 dilution in 3% BSA in
TBST, for 1-1.5 hrs with rocking at room temperature or overnight with rocking at 4°C. It was
then washed three times with TBST before the addition of secondary antibody. The blot was
incubated with an HRP-conjugated secondary antibody at a 1:10000 dilution in 3% BSA in TBST,
for 1-1.5 hrs with rocking at room temperature. The antibody was then washed off the blot
three times with TBST. Finally, the blot was exposed to WestPICO Plus (Life Technologies)
chemiluminescent HRP-reactive substrate, then reacted with X-ray film (Kodak Eastman) and
exposed with an X-ray generator.
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Dynamic Light Scattering
Light scattering experiments were performed on a Zetasizer µV (90° scattering apparatus,
Malvern Panalytical, Malvern, UK) in a 2 µL SUPRASIL quartz cuvette (Hellma Analytics,
Müllheim, Germany) at 3.3°C. The ACLY truncated constructs were tested at 8 µM in sizeexclusion buffer in two independent experiments, six replicates (33 scans per replicate). The
ACLY-FL concentration-gradient experiments used to calculate Dτ at infinite dilution were
carried out in a single independent experiment, with six replicates (33 scans per replicate). The
tested concentrations were 7.2 µM, 5 µM, 3.6 µM, 1.8 µM, and 0.8 µM. The buffer viscosity and
refractive index were calculated with the Zetasizer Software DTS software v7.12 and the protein
refractive index was set to 1.45. The protein hydrodynamic distribution was calculated by the
Zetasizer software and correlation functions were calculated by SEDFIT, using discrete Stokesradii and continuous I(Rh) or I(D)-distribution models. The continuous distributions were
calculated with an equidistant log(1/tau) grid and a confidence level of 0.55. Prism was used to
plot the data and apply a linear regression to calculate the Rh and D at infinite dilution (at the yintercept).

Kinetic Assays
The activity of ACLY was measured according to the method of Linn and Srere95. Briefly, enzyme
activity was determined for protein at 20 nM in 1 mL of 200 mM Tris 8.8, 20 mM MgCl 2, 20 mM
potassium citrate tribasic pH 7.5, 20 mM ATP, and 10 mM DTT with 5U of porcine malate
dehydrogenase (Millipore) and 200 µM NADH (Sigma-Aldrich). The reaction was initiated with
400 µM CoA and allowed to proceed for 20 min at RT during continuous Absorbance340nm
detection in a BioMate 3S spectrophotometer (Thermo Fischer Scientific, Waltham, MA). The
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activity was determined across three independent experiments, n=6 each. Excel (Microsoft,
Redmond, WA) was used to select the linear range of the data (where second derivative = 0) and
to convert ΔAbsorbance into enzyme velocity using the extinction coefficient of NADH. The data
were analyzed in Prism v8.1 for statistical significance and plotted with the median and 95%
confidence interval. The significance of the difference in VMax was determined by two-way
ANOVA with Sidak’s multiple comparisons test. Prism was also used to apply the MichaelisMenten equation to the data to calculate the steady-state kinetic parameters by nonlinear leastsquares approximation.
The pH-dependent activity was determined by substituting the standard reaction buffer for 100
mM sodium acetate, 50 mM Bis-Tris, and 50 mM Tris base at a pH range of 6.0-10.5, with added
20 mM MgCl2, 20 mM potassium citrate tribasic pH 7.5, 20 mM ATP, 10 mM DTT, 2U MDH, 200
µM NADH, and 200 µM CoA used to initiate the reaction. The change in Absorbance340nm was
recorded every 5 five minutes for 1 hour (one experiment, n=5 each).

Differential Scanning Fluorimetry
DSF was carried out with 0.1 mgmL-1 protein that had been dialyzed overnight into DSF buffer
(25mM HEPES 7.5, 200 mM NaCl, 1 mM DTT). SYPRO Orange protein dye (Thermo Fischer
Scientific, Waltham, MA) was added to the protein at a final concentration of 5X, along with
additional buffer, 10 mM MgCl2, 10 mM ATP disodium salt, 10 mM potassium citrate tribasic pH
7.5, and/or 1 mM coenzyme A (all reagents from Sigma-Aldrich) to bring the total volume to 20
µL. The concentrations of these additives were chosen to be at least 20X above the published Kd
(or KM where the Kd was unavailable)93,109, and thus considered to be saturating. The reactions
were set up in a 384-well optical plate (Applied Biosystems, Foster City, CA). The plate was read
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in a 7900HT Real-Time PCR (Applied Biosystems) from 20°C to 95°C at a 2% ramp rate with a 10
min 20°C pre-equilibration step. The raw fluorescence was quantified using the SDS 2.4 software
package. The data were subsequently normalized and taken to the first derivative using Excel,
with the inflection point of the melt curve (the max dy/dx value) used as the TM. To account for
inflections at the beginning of the PCR stage, data outliers were excluded using ROUT analysis,
and the remaining values were tested for significance with a two-way ANOVA with Dunnett’s
multiple comparisons test in Prism v8.1. Individual tests of significance were determined by ttests with Sidak’s multiple hypothesis correction. The data were plotted with the median and
95% confidence interval.

Differential Scanning Calorimetry
The proteins were dialyzed overnight in DSC Buffer (25 mM HEPES pH 8.0, 200 mM NaCl) to
remove any reducing agent, adjusted with the dialysis buffer to 25 µM, and spin-filtered (EMD
Millipore, Burlington, MA) at 18000 xg to remove particulates. Prior to loading into the cell, the
samples were degassed with stirring in an evacuation chamber for 5 min at 10°C. Each sample
was analyzed by MicroCal VP-Capillary DSC (Malvern Panalytical, Malvern, UK), with buffer in
the reference cell. When DSC was used to assess CoA-mediated stabilization, either CoA or
water were added to the protein after dialysis to account for the effect of dilution. DSC buffer
with either CoA or water was used to provide the buffer-only scan. The samples were scanned
from 10.0 °C - 90.0 °C with a 10-min 10.0 °C pre-equilibration and a 30 °C hr-1 or 60 °C hr-1 ramp
rate. Protein refolding (equilibrium) analysis was carried out by cooling the sample from 90 ºC10 ºC at 60 ºC hr-1, with 10 min re-equilibration at 10ºC, and a second 60ºC hr-1 run. The data
were analyzed with the ORIGIN 7.0 VP-DSC package. The data were baselined through a linear
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connect model followed by manual adjustment by cursor. The TM, ΔHCAL, and ΔHvH were
calculated through a non-two state Levenberg-Marquardt least-squares fitting model and
evaluated by reduced χ2 analysis. The average TM, ΔHCAL, and ΔHvH of the data were calculated
using Prism. We report the average weighted estimate ΔHWA as a measure of data quality,
which corrects for experimental baseline fluctuations and the differences between
experiments139. The significance of the difference in TM was determined by an unpaired t-test.

Datasets
All datasets are available at http://dx.doi.org/10.17632/43drcptfgj.1 under a CC 4.0 license.
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